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              Abstract 
Background: Transcranial magnetic stimulation (TMS) is a tool used to measure 
corticospinal excitability. To evaluate the usefulness of TMS as a biomarker in multiple sclerosis 
(MS), the first step is to examine how well variables derived using TMS align with clinical 
symptoms of MS.  
Methods: Participants with MS (n=38) were assigned to motor, cognitive, sensory, or 
asymptomatic clinical group based on their Expanded Disability Status Scale (EDSS) assessment. 
Following recording of demographic information, subjective health and scoring of walking and 
cognition, TMS measures were collected from each brain hemisphere. We first examined whether 
TMS parameters (resting motor threshold (RMT), active motor threshold (AMT), and cortical 
silent period (CSP)) would differ among clinical groups. Next, we examined whether TMS 
parameters predicted severity of symptoms.  
Results: CSP and AMT in the hemisphere corresponding to the weaker hand predicted 
measures of symptom severity among people with MS in the motor and cognitive profile groups. 
Longer CSP was the strongest predictor of slower walking speed (F(1,17)=22.82, p<0.001). Higher 
AMT was the strongest predictor of cognitive impairment using the Montreal Cognitive 
Assessment (F(1,17)==25.29, p=0.001) and perceived physical impact of MS using the Multiple 
Sclerosis Impact Scale-29 (F(1,17)=30.63, p<0.001).  
Conclusions: CSP and AMT in the hemisphere corresponding to the weaker hand 
predicted severity of symptoms among people with MS in the motor and cognitive groups. In these 
cases, TMS variables provided greater predictive value than the traditional EDSS, supporting the 
use of TMS outcomes as biomarkers in MS. 
Keywords: TMS, Biomarker, CSP, AMT 
 iii 
Acknowledgements 
I would like to acknowledge my supervisor, Dr. Michelle Ploughman whose passion in the 
field of Multiple Sclerosis research has always been an inspiration to me. Dr. Michelle Ploughman 
introduced me to the field of Multiple Sclerosis research and provided me with guidance, support 
and motivation throughout this degree. Dr. Michelle Ploughman, I am humbled by your confidence 
in my abilities, and I will be forever grateful to you for providing me with this opportunity.  
 I would also like to acknowledge the members of the Recovery & Performance Laboratory 
for their encouraging words and guidance throughout my project. Without the support of the 
laboratory staff who I now call my “lab family”, this thesis would not have been possible. I would 
also like to thank the members of my committee, Dr. Craig Moore and Dr. Kevin Power, for taking 
the time to review my thesis and provide valuable feedback. 
Lastly, I would like to thank my friends and family, who have supported me throughout 
this journey and been by my side throughout the ups and downs. There are not enough words to 
express my gratitude towards my parents who have instilled upon me a strong passion for learning 
and have done everything possible to lead me down a path of success. I would also like to say a 
special thank you to my boyfriend, who has stood by my side and been my ultimate supporter 
throughout this degree.   
 
 
 
 
 
 
 iv 
Table of Contents 
ABSTRACT ................................................................................................................................................................. II 
ACKNOWLEDGEMENTS ....................................................................................................................................... III 
LIST OF FIGURES ................................................................................................................................................. VII 
LIST OF TABLES .................................................................................................................................................. VIII 
LIST OF ABBREVIATIONS.................................................................................................................................... IX 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW ........................................................................ 1 
1.1 GENERAL INTRODUCTION ................................................................................................................................. 1 
1.2 OVERVIEW OF MULTIPLE SCLEROSIS ............................................................................................................... 4 
1.2.1 Epidemiology ................................................................................................................................................ 4 
1.2.2 Clinical Course in MS ................................................................................................................................... 5 
1.2.3 The Symptoms of MS ................................................................................................................................... 6 
1.2.4 Lesions and Neurodegeneration .................................................................................................................... 8 
1.2.4.1 White Matter Lesions ............................................................................................................................. 8 
1.2.4.2 Grey Matter Damage ............................................................................................................................ 10 
1.2.4.3 The Role of Glutamate and GABA in MS ........................................................................................... 12 
1.2.4.3.1 Glutamate Dysfunction ................................................................................................................. 12 
1.2.4.3.2 GABA Dysfunction ....................................................................................................................... 13 
1.3 MEASUREMENTS OF DISEASE SEVERITY IN MS ............................................................................................ 14 
1.3.1 EDSS and its Usefulness as a Sensitive Outcome Measure ........................................................................ 14 
1.3.2 Biomarkers of MS ....................................................................................................................................... 16 
1.3.3 MRI as a Biomarker .................................................................................................................................... 16 
1.4 TMS..................................................................................................................................................................... 17 
1.4.1 The Corticospinal Tract............................................................................................................................... 17 
1.4.2 Using TMS to Investigate the Integrity of the CST .................................................................................... 20 
1.4.3 TMS Measures of the CST .......................................................................................................................... 23 
1.4.3.1 Motor Threshold................................................................................................................................... 23 
1.4.3.2 Cortical Silent Period ........................................................................................................................... 24 
1.4.4 TMS Abnormalities in Neurological Disorders .......................................................................................... 27 
1.4.4.1 Cognitive Associated Disorders ........................................................................................................... 27 
1.4.4.2 Motor Associated Disorders ................................................................................................................. 28 
1.4.4.3 Sensory and Subclinical Associated Disorders .................................................................................... 30 
1.4.5 What we Know Thus Far: TMS in MS ....................................................................................................... 32 
1.4.5.1  TMS as a Biomarker in MS ................................................................................................................ 32 
 v 
1.4.5.2 The Importance of TMS as a Biomarker at an Individual Level in MS .............................................. 33 
1.5 SUMMARY ......................................................................................................................................................... 34 
CHAPTER 2: METHODS AND RESULTS............................................................................................................ 36 
2.1 METHODS........................................................................................................................................................... 36 
2.1.1 Participants .................................................................................................................................................. 36 
2.1.2 EDSS Classification .................................................................................................................................... 36 
2.1.3 Procedure..................................................................................................................................................... 37 
2.1.3.1 Cognitive Assessments......................................................................................................................... 37 
2.1.3.2 Walking Assessment ............................................................................................................................ 38 
2.1.3.3 Subjective Impact of MS ...................................................................................................................... 38 
2.1.3.4 TMS...................................................................................................................................................... 39 
2.1.4 Statistical Methods ...................................................................................................................................... 41 
2.2 RESULTS ............................................................................................................................................................ 41 
2.2.1 Participants .................................................................................................................................................. 41 
2.2.2 Differences in TMS Measures Between Brain Hemispheres ...................................................................... 44 
2.2.3 Differences in TMS Measures Between Clinical Groups ........................................................................... 46 
2.2.4 Relationship Between Symptom Severity and TMS Measures .................................................................. 49 
2.2.5 Comparison of TMS and EDSS to predict Symptom Severity ................................................................... 54 
CHAPTER 3: DISCUSSION .................................................................................................................................... 60 
3.1 OVERVIEW ........................................................................................................................................................ 60 
3.2 TMS AS A BIOMARKER OF SYMPTOM SEVERITY........................................................................................... 61 
3.2.1 Walking Ability is Best Predicted by CSP in People with Motor and Cognitive MS Profiles ................... 61 
3.2.2 CSP as a Biomarker of Walking Ability in a Clinical Setting .................................................................... 62 
3.2.3 AMT is Predictive of Cognitive Impairment for People with Motor and Cognitive Profiles of MS ......... 64 
3.2.4 Is AMT is Potential as a Biomarker of Cognitive Impairment in a Clinical Setting? ................................ 65 
3.3 TAKING A STEP BACK: TMS IS LESS USEFUL FOR SENSORY AND ASYMPTOMATIC PROFILES OF MS .... 66 
3.3.1 TMS May Help Identify Cerebellar Impairment ........................................................................................ 67 
3.3.1.1 TMS Predicts Symptom Severity for People with Cerebellar Symptoms of MS ................................ 67 
3.3.2 Do TMS Parameters Predict Disease Severity Among People with Exclusive Cognitive Profiles of MS? 68 
3.3.2.1 TMS May be Detecting Subtle CST Abnormalities in Cognitive MS Profiles ................................... 69 
3.3.3 TMS is Not a Suitable Biomarker for Sensory and Asymptomatic MS Profiles ........................................ 70 
3.3.3.1 The Next Generation of Biomarkers: Imaging of Both Brain Structure and Function ........................ 70 
3.4 OTHER TMS PARAMETERS AS POTENTIAL BIOMARKERS IN MS............................................................ 73 
3.4.1 Central Motor Conduction Time ................................................................................................................. 73 
3.4.2 Measures of Intracortical Inhibition ............................................................................................................ 74 
 vi 
3.4.2.1 Short-Interval Intracortical Inhibition .................................................................................................. 75 
3.5 FUTURE DIRECTIONS AND IMPLICATIONS ................................................................................................. 76 
3.5.1 TMS: A Future Component of the ‘No Evidence of Disease Activity’ Paradigm? .................................... 76 
3.5.2 The Use of TMS in a Clinical Setting ......................................................................................................... 77 
3.5.2.1 TMS Addressing Personalized Medicine ............................................................................................. 77 
3.6 LIMITATIONS ..................................................................................................................................................... 78 
3.7 CONCLUSION ..................................................................................................................................................... 80 
REFERENCES ........................................................................................................................................................... 82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
List of Figures
 
Figure 1.1: Corticospinal Tract ...................................................................................................................................................................... 19 
Figure 1.2: Transcranial Magnetic Stimulation ....................................................................................................................................... 21 
Figure 1.3: Motor Evoked Potential Recorded by Electromyography ........................................................................................... 26 
Figure 2.1: TMS Detected hemisphereic differences in ms participants................................................................................ 45 
Figure 2.2: The Difference in CSP Between Clinical MS Profiles.................................................................................................. 47 
Figure 2.3: The Difference in RMT and AMT Between Clinical MS Profiles ........................................................................... 48 
Figure 2.4: The Relationship Between TMS Measures and Symptoms of Disease Severity for Motor and 
Cognitive Profiles of MS ................................................................................................................................................................................. 57 
Figure 2.5: Representative CSP of Two Participants with the Same EDSS ................................................................................ 58 
Figure 2.6: CSP and AMT Detect Changes in People with MS with the same EDSS…………………………………………59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
List of Tables 
Table 1.1: Overview of TMS Measures ....................................................................................................................... 22 
Table 2.1: Participant Demographic Information ........................................................................................................ 43 
Table 2.2: Relationship Between Symptom Severity Measures and CSP of the Weaker Side for Clinical MS Profiles
 ...................................................................................................................................................................................... 50 
Table 2.3: Relationships Between Symptom Severity Measures and Motor Thresholds of the Weaker Side for Clinical 
MS Profiles................................................................................................................................................................... 52 
Table 2.4 Summary of Stepwise Regression Analyses for Predictors of Symptom Severity for Motor and Cognitive 
MS Groups ................................................................................................................................................................... 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
List of Abbreviations 
AMT: Active Motor Threshold 
CNS: Central Nervous System 
CSP: Cortical Silent Period 
CST: Corticospinal Tract 
EDSS: Expanded Disability Status Scale 
EMG: Electromyography 
GABA: γ-aminobutyric acid 
GML: Grey Matter Lesion 
MoCA: Montreal Cognitive Assessment  
MRI: Magnetic Resonance Imaging 
MS: Multiple Sclerosis 
MSIS-29: Multiple Sclerosis Impact Scale-29 
RMT: Resting Motor Threshold 
SDMT: Symbol Digit Modality Test  
TMS: Transcranial Magnetic Stimulation 
WML: White Matter Lesion 
β:  Standardized regression coefficient 
F: F-Statistic 
p: Calculated probability 
R2: Square of the correlation coefficient 
SD: Standard Deviation 
 
 1 
Chapter 1: Introduction and Literature Review 
1.1 GENERAL INTRODUCTION   
Multiple Sclerosis (MS) is a neurodegenerative disease with an unpredictable 
pattern of progression, characterized by inflammation culminating in lesions throughout 
the central nervous system (CNS) (Compston et al., 2005). MS lesions are best described 
as ‘plaques’ or ‘scars’ and are the product of axonal demyelination. These sclerotic lesions 
vary in size and location within the brain and spinal cord, such that the patient experiences 
a diverse array of symptoms (Compston et al., 2005). In most cases, specific MS symptoms 
(i.e. sensory, motor, cognitive) reflect the areas within the CNS which are involved in 
demyelination and are often asymmetrical, as one side of the body (and one side of the 
brain) is more involved than the other (Reich, Smith et al., 2007). Although symptoms 
typically fall under three main categories (motor, cognitive and sensory), in some cases, 
patients may present with an initial attack, leading to their MS diagnosis, with symptoms 
resolving such that people can remain relatively symptom-free for many years (Zipoli, 
Goretti et al., 2010). 
The Expanded Disability Status Scale (EDSS) is a measurement tool used by 
neurologists in order to rate MS disease severity which is a categorical ranking scale of 0 
(no impact of MS) to 10 (death from MS). Although MS is a heterogeneous disease with 
each patient experiencing their own unique set of motor, cognitive and sensory symptoms, 
the EDSS scoring system relies heavily on walking capacity and the measurement of 
changes in other symptoms can be overlooked (Goodkin, Cookfair et al., 1992; Meyer-
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Moock, Feng et al., 2014). Additionally, although individuals may detect declines in 
functional ability and symptom severity, the EDSS is somewhat insensitive to small 
changes in functional ability and/or symptom severity perceived by the patient and may 
underestimate progression (Li, Held et al., 2006). In the future, the effectiveness of new 
treatments will be determined by whether the treatments can halt symptom progression, 
stabilize underlying CNS changes and improve function as reported by the patients 
themselves; indicators that must be measured within clinical trials. Thus, there is a need to 
examine new outcome measures that demonstrate sensitivity and detect heterogeneity in 
MS symptoms in order to assess the benefits of emerging treatments.  
A biomarker is a tool, which objectively measures and evaluates biological changes 
in disease pathology, or responses to therapeutic interventions (Mayeux, 2004). 
Transcranial magnetic stimulation (TMS) is a non-invasive technique used to assess 
excitability within the motor cortex and corticospinal tract (CST). For this reason, variables 
derived using TMS have been a useful biomarkers in other neurological disorders in which 
there is primarily motor dysfunction (stroke and Huntington’s) (Lefaucheur, Ménard‐
Lefaucheur et al., 2006; Carter, Patel et al., 2012; Boyd, Hayward et al., 2017). Research 
investigating TMS as a biomarker in MS has shown questionable efficacy (Simpson & 
Macdonell, 2015). These variable findings could be attributed to the fact that some studies 
group patients who have multiple types of impairment together (motor and non-motor). For 
example, Neva and colleagues (2016), aimed to evaluate a TMS measure called cortical 
silent period (CSP) in MS participants and controls. The CSP has been widely adopted 
when evaluating motor cortex and corticospinal excitability in response to neurologic 
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changes (Khedr, Ahmed et al., 2011; Gray, Palmer et al., 2017). Neva and colleagues 
(2016) found no difference in the CSP duration between MS participants and controls. On 
the other hand, Tataroglu and colleagues (2003), found a significantly prolonged CSP in 
people with MS with motor related impairments (cerebellar) when compared to controls. 
Since MS is a heterogeneous disease, and TMS measures the integrity of a motor tract (not 
sensory or cognitive functions), it would be reasonable to believe that TMS may indeed be 
an effective biomarker when motor impairment is being exclusively investigated in MS. 
For example, several groups have endorsed TMS as a weak biomarker of disease severity 
in MS (Simpson & Macdonell, 2015; Snow, Wadden, Chaves & Ploughman, 2019). 
Because TMS non-invasively examines brain and spinal cord integrity, it has the potential 
to provide a ‘window’ on brain function in MS.  
The work outlined in this thesis aimed to determine whether TMS parameters would 
distinguish groups of MS patients with different clinical profiles, such as motor, cognitive, 
sensory and asymptomatic, from one another. We then evaluated which TMS measures 
predicted symptom severity within the clinical groups compared to the current neurologist 
scored EDSS measure. These preliminary steps are needed to determine whether TMS 
could help detect declines in MS symptoms with better resolution than current measures. 
For the purposes of this thesis, the term TMS is used to describe both the device as well as 
the measures derived from TMS. Since TMS indicates underlying function (or dysfunction) 
of cortical networks, the results of our research are necessary in order to further understand 
whether TMS is a useful biomarker that can track disease progression and detect the effects 
of medication and rehabilitation treatments on neurophysiological processes.  
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This thesis is prepared in the traditional format with three chapters. Chapter One 
provides an overview of MS and associated symptoms, followed by an explanation of 
biomarkers within the field of MS including their limitations. TMS is then described, 
followed by previous research assessing the use of TMS in neurological disorders and the 
use of TMS and its importance within the field of MS. Chapter Two consists of materials 
and methods used to answer the two objectives of this research. The first objective was to 
compare TMS measures between clinical profiles of MS. Secondly, we aimed to determine 
if TMS measures could predict symptom severity and provide better sensitivity than the 
current disease severity measure, EDSS. Chapter Three consists of a discussion 
highlighting the major findings of this research, suggestions for future directions in the 
assessment of TMS as a biomarker for specific clinical profiles of MS, and the limitations 
of this study. The format of this Master’s Thesis is APA style (6th edition). 
 
1.2 OVERVIEW OF MULTIPLE SCLEROSIS 
1.2.1 Epidemiology 
MS is a disabling neurologic disease of the CNS that affects over 2.3 million people 
worldwide (Browne, Chandraratna et al., 2014). Most individuals diagnosed with MS are 
between 20 to 40 years of age, although, younger and older individuals can be diagnosed 
(Rolak, 2003). The cause of MS is still unknown, but evidence supports that environmental, 
lifestyle and genetic factors contribute to the disease. For example, the most common 
environmental factor found to increase the risk of MS is low levels of vitamin D (Cortese, 
Riise et al., 2015; Mokry, Ross et al., 2015). A prevailing lifestyle factor associated with a 
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higher risk of MS is smoking (Hedström, Hillert et al., 2013; Ramanujam, Hedström et al., 
2015). Ramanuham and colleagues (2015) found that smoking tobacco not only increases 
an individual’s risk of MS but has been shown to accelerate the progression of the disease 
(Ramanujam, Hedström et al., 2015). Lastly, the genetic contribution to MS is very diverse; 
however, gene variation on immune response molecules, known as major 
histocompatibility complex molecules, have a large role to play in the increased risk of the 
disease (Consortium, 2005; Ramagopalan, Knight et al., 2009). Thus, it appears that a 
combination of environmental, lifestyle and genetic factors impact a person’s susceptibility 
to MS.  
 
1.2.2 Clinical Course in MS    
MS can be a challenging disease to recognize clinically due to its heterogeneity and 
unpredictable disease patterns. Typically, patients experience a clinically isolated 
symptom, such as unilateral optical neuritis or partial myelopathy (Thompson, Banwell et 
al., 2018). A clinically isolated symptom initiates further investigation by a patient’s 
neurologists using the 2017 revised McDonald criteria, outlining a combination of criteria 
used for MS diagnosis (Thompson, Banwell et al., 2018). Such criteria include MRI 
imaging, cerebrospinal fluid analysis, blood tests to rule out other conditions, along with a 
neurological examination. Additionally, the revised McDonald criteria in 2017 introduced 
a new criterion to aid in MS diagnosis; the presence of oligoclonal bands which can be 
detected in the cerebrospinal fluid using MRI (Thompson, Banwell et al., 2018). 
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Even though patterns of disease progression are inconsistent, two main clinical 
forms that classify a patient’s disease course are known as relapsing-remitting or 
progressive. The most common presentation of MS typically diagnosed is relapsing-
remitting MS, characterized by clearly defined periods of relapse, with full or partial 
remission (Compston et al., 2005). Approximately 40-50% of people who have relapsing-
remitting MS will transition into secondary progressive MS after 20 years of disease onset 
(Compston et al., 2005). Secondary progressive MS is characterized by continuous 
progressive decline with either no remissions or minor remissions (Rovaris, Confavreux et 
al., 2006). The second clinical form of MS diagnosed in 10% of patients is primary 
progressive MS. Primary progressive MS has a vague onset in which patients experience 
progressive decline from disease onset with occasional plateaus and possible minor 
improvements (Compston et al., 2005). In general, research has focused on comparing 
clinical biomarkers of disability between relapsing-remitting MS, secondary progressive 
MS, and primary progressive MS because they are well defined clinical courses of MS. 
Nevertheless, the symptoms of MS vary substantially from person to person and as a result, 
finding a biomarker that can distinguish patients by their profile of symptoms is 
challenging. 
 
1.2.3 The Symptoms of MS  
Because lesions are widespread; varying in size and severity, the symptoms of MS 
and how they are experienced are highly variable. The EDSS, one of the oldest and most 
widely utilized assessment instruments in MS (Kurtzke, 1983), groups symptoms into 
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seven main categories which include pyramidal, cerebellar, brainstem, sensory, bowel, and 
bladder, visual and cerebral (mental) functions. Pyramidal symptoms involve motor 
dysfunction such as limb weakness, paresis or spasticity. Cerebellar and brainstem 
dysfunction may manifest as double vision, dizziness, cerebellar ataxia, tremor, spasticity, 
facial sensory loss and vertigo (Browne, Chandraratna et al., 2014). Symptoms of bowel 
and bladder dysfunction may involve urinary hesitancy, urgency, retention, incontinence 
or loss of bowel function (DasGupta & Fowler, 2003). Sensory dysfunction is very frequent 
in people with MS involving pain or unpleasant feelings of vibration in the limbs, decreased 
ability to feel touch, position sense, or vibration, and in extreme cases, loss of sensation in 
the limbs or below the head (Beiske, Pedersen et al., 2004). In terms of visual dysfunction, 
optic neuritis, defined as blurring of vision in one eye and possible pain or light flashes 
during eye movement, is a common presenting symptom experienced by people with MS 
(Brownlee, Hardy et al., 2017). Lastly, symptoms classified as ‘cerebral function’ affect 
43-70% of people with MS (Chiaravalloti & DeLuca, 2008). Symptoms may include 
problems with memory and even dementia. While the functional system scale within the 
EDSS includes a wide variety of symptoms, there are several distinct symptoms that are 
not included in the EDSS, which are extremely common among patients with MS, 
including fatigue (Bakshi, Shaikh et al., 2000), mental health symptoms (anxiety and 
depression) (Beiske, Svensson et al., 2008), heat intolerance (White, Wilson et al., 2000), 
and sexual dysfunction (DasGupta & Fowler, 2003). 
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1.2.4 Lesions and Neurodegeneration  
1.2.4.1 White Matter Lesions 
The pathologic hallmark of MS consists of multiple focal areas of plaques as a 
product of demyelination, axonal damage and oligodendrocyte death within the CNS 
(Compston et al., 2005). The most common areas for plaques to appear is in white matter, 
which consists of myelinated axons that form connections between brain cells and are 
distributed into bundles called tracts (Fields, 2008). Plaques of white matter are commonly 
found in areas that contain many small vessels, such as around ventricles or outer surfaces 
of the brainstem or spinal cord  (Lassmann, Bruck et al., 2007; Pardini, Sudre et al., 2016). 
Further, white matter lesions (WMLs), have been described as a product of demyelination 
and inflammation, involving the action of immune cells infiltrating parenchyma of the CNS 
due to the disturbance of the blood brain barrier (Compston et al., 2005; Hochmeister, 
Grundtner et al., 2006). The healthy immune system exhibits self-tolerance and limits 
attack on the body’s own proteins and antigens, yet, in MS, immune cells unpredictably 
attack one’s own myelin antigens (Compston et al., 2005). The inflammatory response 
involves lymphocytes (predominantly T cells), macrophages and glial cells. In MS, while 
there are many types of T cells involved in pathology, it is thought that CD4+ (helper) T 
cells play a role in initiation of lesions while CD8+ (cytotoxic) T cells dominate and 
multiply at the demyelinated site, far outnumbering CD4+ T cells (Babbe, Roers et al., 
2000; Lassmann, 2005). It is believed that in MS, T cells cross the blood brain barrier and 
initiate the up-regulation of innate molecules of the immune system called microglia, which 
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are found to be prominent in all actively demyelinating lesions (Lassmann, Bruck et al., 
2007; Zrzavy, Hametner et al., 2017).  
While MS was thought to be predominantly mediated by T-cells, emerging research 
using anti-CD20 therapies and their approval in treating relapsing-remitting and primary-
progressive MS have highlighted the role of B cells in CNS inflammation (Li, Patterson & 
Bar-Or, 2018). In two identical phase three trials, Hauser and colleagues (2017) assigned 
821 MS participants to receive ocrelizumab (a monoclonal antibody that depletes CD20+ 
B cells) and 835 MS participants to receive interferon beta-1a (Hauser et al., 2017). It was 
discovered that ocrelizumab was significantly associated with lower rates of disease 
activity and progression compared to interferon beta-1a (Hauser et al., 2017). Further, it is 
suggested that the reduction of CD20+ B cells may prevent their contribution to MS 
through mechanisms such as proinflammatory-cytokine-mediated activation and antigen 
presentation (Li, Patterson & Bar-Or, 2018). It is also plausible that reduction of CD20+ B 
cells may prevent peripheral cellular immunological cascades involved in triggering new 
relapses (Li, Patterson & Bar-Or, 2018). 
Another consequence of the immunologic response is the death of a group of 
specialized cells within the CNS that produce the myelin sheath, called oligodendrocytes. 
Oligodendrocyte death occurs at the border of MS lesions; the same areas where high 
densities of microglia have been discovered (Peterson, Bö et al., 2001). This suggests that 
microglia may have a role to play in oligodendrocyte death, preventing remyelination of 
CNS axons. Although microglial cells are recognized for their damaging effects, they also 
play a dual role in MS as they possess anti-inflammatory properties and release growth 
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factors which have the ability to support axonal remyelination (Domingues, Portugal et al., 
2016); despite this, the underpinnings of this dual role remain unclear (Vogel, Vereyken et 
al., 2013; Prinz & Priller, 2014; Luo, Jian et al., 2017). Overall, WMLs are areas of 
inflammation and demyelination scattered throughout the white matter and are highly 
variable in size and location, ultimately contributing to the array of clinical symptoms 
experienced by people with MS (Popescu, Pirko et al., 2013). 
 
1.2.4.2 Grey Matter Damage 
MS was traditionally considered a disease affecting white matter within the CNS. 
It has now been established that disruption of nerve cells (cortical grey matter) is an 
additional component of MS  (Pirko, Lucchinetti et al., 2007; Geurts & Barkhof, 2008). 
The most susceptible regions for grey matter damage within the CNS include the motor 
cortex, cerebellum and deep grey matter nuclei (Calabrese, Agosta et al., 2009; Gilmore, 
Donaldson et al., 2009). Four main forms of grey matter damage have been described: 
Types I, II, III and IV. Type I are leucocortical lesions of the cortex that extend from 
subcortical white matter (Wu & Alvarez, 2011). Type II are intracortical lesions, found 
within the cortex while type III are subpial lesions that appear along the pial surface, 
extending to layers III or IV of the cortex. Lastly, type IV grey matter lesions encompass 
the  width of the cortex, spreading over several gyri and lobes of the cortex (Bø, Vedeler 
et al., 2003; Calabrese, Filiippi & Gallo, 2010). While it has been noted that grey matter 
lesions (GMLs) have much less inflammation with fewer associated T-cells, macrophages 
and microglia than WMLs (Peterson, Bö et al., 2001). However, recent findings from 53 
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patient cortical biopsy samples suggested that there is an inflammatory profile within 
GMLs (Lucchinetti, Popescu et al., 2011). In accordance with new research, inflammation 
has been noted as a key driver of GMLs (Lagumersindez-Denis, Wrzos et al., 2017). 
Another unique feature of GML is the lack of breakdown of the blood brain barrier (van 
Horssen, Brink et al., 2007), leading to the concept that T-cells gain entry into the brain via 
the meninges, choroid plexus or subarachnoid space (Prins, Schul et al., 2015). Although 
the pathology of GML is becoming clearer, the exact mechanism of GML formation 
remains unknown. Overall, GMLs are difficult to detect on routine clinical imaging and 
require more sophisticated ultra-high field 7 Tesla magnetic resonance imaging (MRI). 
imaging technique (Kilsdonk, Jonkman et al., 2016). With advancing importance of GML 
contribution to symptomology of MS, there is increasing need for a biomarker of disease 
progression beyond clinical MRI imaging. 
Studies linking WML and GML lesions to clinical symptoms suggest that there is 
often a mismatch between imaging results and clinical MS profile. For example, while 
WML size and location could not always explain clinical deficits in people with MS, GML 
accumulation further explained clinical disability (Calabrese, Agosta et al., 2009; Hulst, 
Schoonheim et al., 2012; Schoonheim, Popescu et al., 2012). In fact, recent research 
suggests that GMLs may give rise to motor symptoms of MS. For instance, in 172 people 
with MS, greater cerebellar grey matter abnormalities (measured by conventional MRI) 
predicted greater motor impairment (EDSS) (Preziosa, Rocca et al., 2014). In summary, 
WML and GML cause dysfunction within functional brain networks as well as ascending 
and descending projections and contribute to a variety of symptoms experienced by people 
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with MS. There is not always a clear correlation between appearance of WML and GML 
and clinical symptomology.  
 
1.2.4.3 The Role of Glutamate and GABA in MS  
1.2.4.3.1 Glutamate Dysfunction 
Neurotransmitters are released at the neuronal synapse allowing signals to transmit 
from one neuron to another (Zimmerman & Wee, 1984). Excitatory neurotransmitters 
increase the chance that the postsynaptic neuron will produce an action potential while 
inhibitory neurotransmitters decrease the probability of neuronal propagation. The 
neurotransmitter glutamate (excitatory) is the most abundant neurotransmitter in the brain, 
which allows neurons to work together to carry out complex functions including but not 
limited to cognition, sensory information, motor coordination (Hassel & Dingledine 
,2012). Despite this, glutamate is not a “more is better” molecule. In MS, CNS degeneration 
including neuronal damage, is partially caused by overactivity of glutamate, better known 
as excitotoxicity (Stojanovic, Kostic et al., 2014). Research in both animal models and 
cohorts of MS patients suggest that neuronal damage within the CNS is partially due to 
higher concentrations of glutamate (Werner, Pitt et al., 2001; Azevedo, Kornak et al., 
2014). In animal models of MS, increased levels of glutamate contribute to the production 
of demyelinated lesions (Werner, Pitt et al., 2001). Similarly, among 343 patients with MS, 
increased serum glutamate levels predicted an increased rate of axonal deterioration 
(measured by serum concentrations of N-acetylasparate using multivoxel spectroscopy) 
over a 5-year time period (Azevedo, Kornak et al. 2014).  It was further determined that 
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higher glutamate levels and corresponding N-acetylasparate levels were associated with a 
loss of brain volume, decline in cognitive function, and increased disability score 
(Azevedo, Kornak et al., 2014). Increased glutamate levels lead to excitotoxicity, resulting 
in axonal demyelination, synaptic dysfunction and cellular death. Techniques to track 
glutamate actions may be beneficial in order to detect disease progression and measure the 
benefits of future disease-modifying therapies.  
 
1.2.4.3.2 GABA Dysfunction  
Within the CNS, γ-aminobutyric acid (GABA) is the main inhibitory 
neurotransmitter  (Paul, Branton et al., 2014). Low GABA levels have been detected in MS 
and have been found to correlate with disability (Cawley, Solanky et al., 2015; Nantes, 
Zhong et al., 2016). In a study by Cawley and colleagues (2015), low levels of GABA in 
sensorimotor brain regions (quantified by using single voxel MEGA-PRESS magnetic 
resonance spectroscopy) were reported in 30 people with secondary progressive MS 
compared to 17 healthy controls (Cawley, Solanky et al., 2015). Moreover, lower levels of 
GABA significantly correlated with greater physical disability (muscle and grip strength) 
in MS participants (Cawley, Solanky et al., 2015). Similarly, Nantes and colleagues (2016) 
found that lowered sensorimotor GABA levels (collected using proton magnetic resonance 
spectroscopy) were linked to worse motor performance on upper limb motor function using 
the 9 Hole Peg Test (Nantes, Zhong et al. 2016). In summary, MS-related disability, and 
likely neuronal modification during injury and repair, are related to altered levels of GABA 
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neurotransmitter levels. There is a clear need for non-invasive methods to measure 
glutamate and GABA–mediated activity as a potential indicator of disease progression. 
 
1.3 MEASUREMENTS OF DISEASE SEVERITY IN MS  
1.3.1 EDSS and its Usefulness as a Sensitive Outcome Measure 
Despite years of criticism by researchers and clinicians, EDSS remains the most 
standard clinician-reported outcome tool used by neurologists to rank MS disease severity 
(Meyer-Moock, Feng et al., 2014). The EDSS scoring system is a categorical scale that 
ranges from no impairment (0) to death (10) in 0.5 increments (Kurtzke, 1983). Within the 
scale, scores from 0 to 3.5 indicate good functional status with no assistance required; 
scores between 4.0 to 5.5 suggest impaired walking and people who score between 6.0 and 
9.0 require progressively more assistance in activities of daily living.  
EDSS has three major weaknesses. First, the EDSS rating system prioritizes 
impairments in physical functioning, minimizing the contributions of other functional 
domains such as cognition and sensation. Secondly, people with MS who have unique 
patterns of symptoms may receive the same EDSS score and potentially receive similar 
treatment for different MS symptoms. Thirdly, since the EDSS rubric is essentially a 
categorical scale that has been assigned numerical values, it is relatively insensitive to 
small changes experienced by the patient and may underestimate progression. For example, 
researchers explain that EDSS has limited responsiveness to change in disability, which 
means that even though individuals may notice small changes occurring, the EDSS score 
may not change (Hobart, Lamping et al., 2001). Marolf and colleagues (1996) investigated 
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changes in disability scores before and after in-patient rehabilitation and found that 68% 
of disability scores were unchanged using the clinical disability tool Functional-
Independence Measure while 95% of disability scores were unchanged using the EDSS 
(Marolf, Vaney et al., 1996). Similarly, in more recent research, Rabadi and Vincent (2013) 
reported that within 76 veterans with MS, the Functional Independence Measure was a 
more sensitive measure of MS disability than the EDSS (Rabadi & Vincent, 2013). Despite 
these findings, EDSS continues to remain the most common neurologist-used outcome tool 
(Meyer-Moock, Feng et al., 2014). As a consequence of poor EDSS responsiveness, 
clinicians may have been able to intervene and stop these declines in ability, but by the 
time EDSS score changes, a large change in ability has already occurred. Another well-
documented weakness of the EDSS is the poor inter-rater reliability which means that a 
patient with MS may receive two different EDSS scores from two different neurologists 
(Meyer-Moock, Feng et al., 2014). More specifically, different ranges of the scale have 
different levels of inter-rater reliability, with EDSS scores from 1.0 to 3.5 reported to have 
the greatest inter-rater scoring variability (Goodkin, Cookfair et al., 1992). 
Altogether, while EDSS is one of the most popular disease severity tools, it lacks 
sensitivity has a low ability to detect heterogeneity and poor inter-rater reliability. Thus, it 
is increasingly recognized that there is a critical need for new measures that are sensitive 
to small changes in MS symptoms in order to better target treatments. As everyone with 
MS has their own unique symptoms and pattern of progression it is critical to use a tool 
which addresses EDSS weaknesses. Imaging and neurophysiological biomarkers provide 
an opportunity to sensitively measure change within the clinical profiles of MS, perhaps 
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providing greater granularity than the EDSS and providing a window into the biological 
underpinnings of disease progression. 
 
1.3.2 Biomarkers of MS 
A biomarker in clinical research is an objective tool that indicates a change in 
underlying disease pathology (Mayeux, 2004). Above all, biomarkers can open the door 
for personalized medicine, providing the opportunity to track disease progression and 
provide a personal care plan on an individual level (Polivka, Krakorova et al., 2016). In 
stroke, both functional MRI or TMS can help measure the integrity of the corticospinal 
tract (CST) which, in turn, predicts potential for recovery (Braune & Fritz, 1995; Ahonen, 
Jehkonen et al., 1998; Carter, Patel et al., 2012; Lotze, Beutling et al., 2012). Unfortunately, 
due to the complexity and unpredictability of MS, finding an accurate and reproducible 
biomarker has been a notoriously complicated task (Katsavos & Anagnostouli, 2013). 
Discovery of a useful biomarker of disease severity could be used by clinicians to initiate 
earlier intervention or to track and observe the effects of drugs and rehabilitative 
treatments.   
 
1.3.3 MRI as a Biomarker 
MRI is notably the most accurate tool for early MS diagnosis and has been 
recognized as the gold standard method for monitoring MS  (Wattjes, Steenwijk et al., 
2015). While conventional MRI detects early indication of MS plaques within the CNS, 
these techniques are confined to structural change and are unable to identify functional 
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changes within neuronal pathways and networks (Gajofatto, Calabrese et al., 2013). 
Furthermore, lesion load, collected by conventional MRI (proton density/T2-weighted), 
has been found to only weakly correlate with clinical disability (Kappos, Moeri et al., 1999; 
Li, Held et al., 2006; Fisniku, Brex et al., 2008). Li and colleagues (2006) collected MRI 
data from a database of 1,312 MS patients and determined that lesion load, in fact, 
correlated with disability (EDSS) in MS patients with EDSS scores up to 4.5 (Li, Held et 
al., 2006). However, it was found that for scores above 4.5, indicating an increased 
disability, there was a plateau in the relationship (weak to moderate correlation) with lesion 
load. More recently, advanced 7-Tesla MRI techniques permit the detection of grey matter 
pathology and undiscovered cortical lesions (Vigeveno, Wiebenga et al., 2012; Kilsdonk, 
Jonkman et al., 2016). Therefore, more advanced biomarker techniques may help to explain 
symptomology. However, MRI is a technique that is resource-heavy as it is costly and time-
consuming in order to capture high-quality images (Mills, Mirza et al., 2017). TMS may 
have the ability to address these weaknesses inherent with MRI as it is more resource-
efficient and has the capacity to provide function-related changes within the CST.  
 
1.4 TMS  
1.4.1 The Corticospinal Tract  
The CST is a white matter tract in the body, known as the principal motor system for 
controlling voluntary movements (Martin, 2005). The CST begins at the cortex, extends 
through deep white matter continuing to the brainstem. Once at the brainstem, 
approximately 75-90% of fibers cross from one side to the other in the medulla which is 
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known as pyramidal decussation (Martin, 2005). These fibers which descend contra-
laterally are called the lateral CST, controlling the movements of the limbs of the opposite 
side of the body. The anterior CST account for the remaining 10-25%, which does not cross 
at the levels of the medulla but continues to descend and control the movement of the trunk 
(Martin, 2005). In particular, damage to the CST leads to impaired motor function (e.g., 
limb weakness and paresis) as seen in neurological disorders such as stroke  (Vargas, 
Gaudron et al., 2013) and MS (Daams, Steenwijk et al., 2015). Moreover, TMS has the 
ability to a assess the integrity and excitability (the propensity of a neuron to generate an 
action potential) of the CST. See Figure 1.1 for CST 
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FIGURE 1.1: CORTICOSPINAL TRACT 
The corticospinal tract beginning at the motor cortex, running through the internal capsule 
to the pyramids where the lateral corticospinal tract will descend contralaterally and the 
anterior corticospinal tract will descend ipsilaterally. Reprinted from Corticospinal System, 
In https://www.flickr.com/photos/interactive-content/. Copyright 2017 by Chest Heart & 
Stroke Scotland and The University of Edinburgh. Reprinted with permission. 
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1.4.2 Using TMS to Investigate the Integrity of the CST 
TMS is a non-invasive technique that delivers magnetic stimulation over targeted 
regions of the brain which can be used for different purposes.  For instance, repetitive TMS 
is a special form of TMS that delivers trains of pulses to the brain which has been approved 
in some countries for treating depression (Perera et al., 2016). The second key use of TMS 
is as a biomarker to probe corticospinal excitability and patterns of inhibition and excitation 
of neuronal networks (Zipser et al., 2018). In several neurological disorders, TMS applied 
over the motor cortex helps to map the functionality of the CST and understand underlying 
neuronal network integrity and dysfunction (Caramia, Cicinelli et al., 1991; Caramia, 
Palmieri et al., 2004; Hallett, 2007; Ni & Chen, 2015). To assess the CST, a coil is held at 
an optimal position of 45° over the skull corresponding to the region of interest in the motor 
cortex.  The device emits a magnetic pulse (Figure 1.2) (Hallett, 2007) and the current 
painlessly depolarizes cortical neuronal networks of the motor cortex beneath the scalp and 
transmits an electrical signal to the corresponding muscle. A muscle contraction induced 
by the TMS is termed motor evoked potential (MEP) and is quantified by 
electromyography (EMG). MEPs can be quantified in several different ways which will be 
discussed. A summary of TMS measures are provided in Table 1.1. 
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FIGURE 1.2: TRANSCRANIAL MAGNETIC STIMULATION 
Participant seated in TMS chair with a coil placed tangentially to the scalp over the motor 
cortex. (A) The TMS coil placed on a 45° angle over the motor cortex (B) The EMG device 
wrapped around the wrist with electrodes on the skin over the muscle of interest. In our 
current study, the coil would be placed on the opposite side of the wrist with the electrodes; 
however, in this figure, assessment of ipsilateral connectivity was being evaluated (C) The 
TMS Brainsight Neuronavigation software ensures accurate positioning of the TMS coil.  
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TABLE 1.1: OVERVIEW OF TMS MEASURES 
TMS Measure (Single Pulse) How it is collected  What it provides 
Resting Motor Threshold (RMT) % Maximal stimulator 
output which evoked 5 out 
of 10 MEPS of ≥ 50μV 
during muscle relaxation 
Quantification of overall 
corticospinal excitability 
 
Active Motor Threshold (AMT) % Maximal stimulator 
output which evoked 5 out 
of 10 MEPS of ≥ 20μV 
during 10-15% of maximal 
voluntary contraction 
Quantification of overall 
corticospinal excitability 
during muscle 
contraction 
Cortical Silent Period (CSP) The average time from the 
end of the MEP to the 
return of voluntary EMG 
activity of 5 out of 10 
successful MEPS from 
AMT 
 
Degree of muscle 
interruption after muscle 
contraction: an indicator 
of brain and spinal 
inhibition  
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1.4.3 TMS Measures of the CST 
1.4.3.1 Motor Threshold 
 In order to elicit a MEP in the target muscle, a certain intensity of TMS output is 
needed, termed the motor threshold; an indicator of corticospinal excitability (Hallett, 
2007). To determine motor threshold, the first step is to identify the “hotspot” which is the 
cortical area most responsible for the TMS-evoked muscle contraction. In order to find the 
hotspot, TMS is applied to various sites over the primary motor cortex. The site which 
produces the highest muscular response (MEP peak-to-peak amplitude) in the muscle of 
interest is chosen as the hotspot. According to criterion of the relative frequency method 
described by Groppa and colleagues (2012), resting motor threshold (RMT) is collected 
while the muscle of interest is at rest, determined as the minimum amount of maximum 
stimulator output (MSO%) of the TMS needed to evoke 5 out of 10 MEPs of ≥ 50μV 
(Groppa et al., 2012). Active motor threshold (AMT) is similar to RMT; however, it is 
collected while an individual contraction the muscle of interest to 10% of their maximum 
voluntary contraction. AMT is defined as the minimum MSO% needed to evoke 5 out of 
10 MEPs of ≥ 200μV (Groppa et al., 2012). Abnormally high threshold (RMT or AMT) 
values may indicate dysfunction of the CST stemming from a variety of neuronal factors 
such as a decrease in excitatory projections from the motor cortex. In other words, in 
individuals with decreased excitatory projections from the motor cortex, a higher 
stimulator output from TMS would be needed to elicit a response in the corresponding 
muscle of interest.  
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1.4.3.2 Cortical Silent Period 
Once a MEP has been produced during voluntary muscle contraction (AMT), there 
is a period of time (post contraction) when there is a silencing of EMG activity termed the 
CSP (Triggs, Macdonell et al., 1992). The CSP is obtained from 5 out of 10 of the 
successful MEPs from AMT collection. The typical method to calculate the CSP is to take 
the interval (in ms) from the time of the end of the MEP to the return of the background 
EMG activity (Figure 1.3) (Modugno, Curra et al., 2001). Physiological underpinnings of 
the CSP remain a highly discussed topic, however it has been accepted that the CSP is the 
product of both cortical and spinal inhibition (Fuhr, Agostino et al., 1991; Inghilleri, 
Berardelli et al., 1993; Ziemann, Netz et al., 1993; Ahonen, Jehkonen et al., 1998). 
Additionally, researchers attribute the production of CSP to the GABAB inhibitory neuronal 
system within the CNS (McDonnell, Orekhov et al., 2006; Stetkarova & Kofler, 2013). 
Recent research by Tremblay and colleagues (2012) investigated the relationship between 
the CSP and measures of GABA and glutamate in a population of 24 healthy volunteers, 
measured by proton magnetic spectroscopy and TMS (Tremblay, Beaulé et al., 2012). 
Interestingly, it was determined that higher glutamate levels were predominantly linked to 
longer CSP. Concentrations of GABAB were not correlated with CSP; however, glutamate 
levels were linked to higher levels of GABA. As a result, Tremblay and colleagues (2012) 
suggested a possible homeostatic link between both glutamate and GABAB 
neurotransmitter systems within the CNS, meaning that, in response to higher glutamate 
concentration, GABAB may increase its inhibitory activity to counterbalance excitation. 
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While the mechanisms of the CSP remain highly discussed, CSP continues to be a measure 
of interest in MS research when determining the integrity of the CST. 
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FIGURE 1.3: MOTOR EVOKED POTENTIAL RECORDED BY 
ELECTROMYOGRAPHY 
Example of a motor evoked potential (MEP) from the first dorsal interosseous muscle 
following TMS over the primary motor cortex. The TMS artifact is indicated at Time 0. 
The background electromyography (EMG) activity is the activity of the muscle of interest 
at rest before a MEP of the muscle is elicited. Following the MEP there is a period of EMG 
suppression, which is termed the cortical silent period (CSP). 
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1.4.4 TMS Abnormalities in Neurological Disorders  
1.4.4.1 Cognitive Associated Disorders 
In neurological conditions, abnormal neurophysiological measurements collected 
from TMS have been associated with motor, cognitive, and sensory symptoms and even 
with neuropathological abnormalities in the absence of clinical symptoms (Eisen, Bohlega 
et al., 1989; Heald, Bates et al., 1993; Catano, Houa et al., 1996; Ahonen, Jehkonen et al., 
1998; Lorenzano, Dinapoli et al., 2006; Schippling, Schneider et al., 2009; Khedr, Ahmed 
et al., 2011; Gray, Palmer et al., 2017). For example, among people with Alzheimer’s 
disease, characterized by a decline in memory, reasoning, and executive function, there is 
prolonged CSP and reduced corticospinal excitability, measured using RMT and AMT 
compared to controls. Khedr and colleagues (2011) reported prolonged CSP in 45 patients 
with Alzheimer’s disease as compared to 37 healthy controls (Khedr, Ahmed et al., 2011). 
Additionally, CSP was found to significantly increase with disease severity (mild, 
moderate, severe) (Khedr, Ahmed et al., 2011). Despite these findings, prolonged CSP may 
not be a consistent hallmark of Alzheimer’s disease since Inghilleri and colleagues (2006) 
failed to find CSP differences between 20 Alzheimer’s patients and 20 healthy controls. 
The authors suggested that equivocal values could be due to GABA-ergic neurons being 
preserved in Alzheimer’s disease (Inghilleri, Conte et al., 2006). Nonetheless, analysis of 
the CSP among people with MS who may have cognitive impairment is worthy of 
investigation due to some shared cognitive symptom characteristics with Alzheimer’s 
disease. 
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 Studies analyzing other TMS measures such as motor threshold in patients with 
Alzheimer’s disease report lower RMT (Di Lazzaro, Oliviero et al., 2004; Khedr, Ahmed 
et al., 2011) and AMT (Khedr, Ahmed et al., 2011). In contrast, Nardone and colleagues 
(2008) found no changes in RMT and AMT between 17 Alzheimer’s disease patients and 
22 healthy controls; however, the patients included in the study had a diagnosis of probable 
Alzheimer’s disease and were described as being in the in milder stages. The authors 
suggested that impaired cortical excitability may not be apparent at these early stages and 
recommended testing patients who would be further along in the disease course. (Nardone, 
Bergmann et al., 2008). It is important to keep in mind that while Alzheimer’s disease and 
MS have similar cognitive symptoms (processing speed, attention, memory), the 
pathological underpinnings are vastly different. Nevertheless, is possible that people with 
MS who experience primarily cognitive symptoms may also demonstrate altered CSP and 
motor thresholds. This phenomenon has yet to be examined.  
 
1.4.4.2 Motor Associated Disorders 
Since TMS measures the integrity of the CST, it is not surprising that TMS 
measures align with severity of symptoms in neurological disorders that affect the motor 
system such as stroke (Braune & Fritz, 1995; Ahonen, Jehkonen et al., 1998) and 
Huntington’s disease (Modugno, Curra et al., 2001). For over twenty years, TMS has been 
evaluated as a clinical biomarker in stroke. In 1998, Ahonen and colleagues performed 
TMS on 29 patients with ischemic stroke and found that the mean CSP was significantly 
prolonged on the affected side of the brain compared to the un-affected side, supporting 
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the ability of CSP to detect even small subclinical disturbance in motor function (Ahonen, 
Jehkonen et al., 1998). Several other studies confirmed the presence of prolonged CSP in 
the ipsilesional hemisphere (Braune & Fritz 1995; Liepert, Bauder et al., 2000; Gray, 
Palmer et al., 2017). Not surprisingly, using motor thresholds, studies have shown a higher 
threshold of the affected hemisphere as compared to the unaffected hemisphere (Heald, 
Bates et al., 1993, Catano, Houa et al., 1996). These findings demonstrate that TMS is 
useful to detect abnormal corticospinal excitability by probing the CST and is sensitive to 
differences in damage between brain hemispheres.  
Huntington’s disease is a genetic neurological disorder characterized by 
progressive motor incoordination. In Huntington’s research using TMS, two separate 
studies with sample sizes of 11 and 17, demonstrated significantly prolonged CSP in 
patients compared to controls (Modugno, Curra et al., 2001; Lorenzano, Dinapoli et al., 
2006). Eisen and colleagues (1989) reported shortened CSP in 7 of 9 Huntington’s patients 
as compared to 13 healthy controls (Eisen, Bohlega et al., 1989). Considering that 
Huntington's disease is characterized by a mixture of motor and non-motor symptoms, 
measurements of RMT and AMT have been inconclusive. For example, Schippling and 
colleagues (2009) found that 8 premanifest Huntington’s gene carriers and 8 early 
symptomatic Huntington’s patients displayed an increase in both RMT and AMT as 
compared to 22 healthy controls (Schippling, Schneider et al., 2009). In contrast, Orth and 
colleagues (2010) found no differences in RMT and AMT between 15 Huntington’s 
carriers compared to 14 controls (Orth, Schippling et al., 2010). Overall, the evidence 
supports that there may be prolonged CSP and increased RMT and AMT in patients who 
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have neurological disorders that at least in part, involve the motor system. Therefore, it is 
plausible that people with MS with primarily motor symptoms would also display similar 
abnormalities in these TMS measurements.  
 
1.4.4.3 Sensory and Subclinical Associated Disorders 
There are limited studies that have evaluated the integrity of the CST using TMS 
among people who have primarily sensory disorders. This may be due to the fact that 
sensory dysfunction involves primarily sensory cortex, nuclei, and tracts, rather than the 
CST. Epilepsy is one disorder in which abnormal brain activity  (seizure) can result in 
unconsciousness, abnormal sensations and bodily movements (Wolf, 2016). The mixed 
presentation in epilepsy makes it an interesting disorder to evaluate using TMS measures. 
Reutens and colleagues (1993) found reduced RMT in 20 patients with idiopathic 
generalized epilepsy as compared to 23 control subjects (Reutens, Berkovic et al., 1993). 
Conversely, Macdonell and colleagues (2001) found no difference in RMT; though, 
reported a prolonged CSP in 21 patients compared to 19 healthy controls (Macdonell, King 
et al., 2001). Some authors suggest that TMS may be able to detect alterations in 
interconnectivity between the sensory and motor cortices which could be useful to map the 
neurological underpinnings of sensory disorders (Amadio, Houdayer et al., 2014).  
TMS may also reveal pathophysiological abnormalities among people who have 
pain. In a recent systematic review (Nardone, Versace et al., 2019), the authors reported 
that people with pain show some TMS abnormalities when using paired–pulse TMS 
methods (inhibition and facilitation) but not changes in thresholds and CSP. Whether 
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people with MS having sensory symptoms would have changes in corticospinal excitability 
detectable using TMS is not known and requires further consideration. 
MS is a disease in which patients can often experience long periods of remission. 
If assessed by their neurologist, they may be considered ‘asymptomatic’ or ‘subclinical’. 
This group is interesting to examine using TMS because patients may be experiencing 
changes at the neuropathological level that are not yet apparent to the outside observer. 
Concerning such subclinical neurological disorders, there has been minimal investigation 
of CST abnormalities using TMS. MS has a prodromal period that has been reported to be 
up to five years, in which patients experience vague neurological symptoms (Wijnands, 
Zhu et al., 2019) that are not detected by current clinical measures. This means that 
individuals, before being diagnosed with MS, appear asymptomatic, meanwhile, 
pathophysiological processes are occurring (Högg, Wijnands et al., 2018). These two 
groups of people with MS (people with preclinical prodromal symptoms or who are in 
remission) are interesting to study. If better biomarkers could be developed, then 
intervention could begin more promptly. In terms of using TMS as a potential biomarker, 
Tataroglu and colleagues (2003) found that people with MS with no clinical symptoms had 
a prolonged CSP compared to controls (Tataroglu, Genc et al., 2003). With little evidence 
in the field of asymptomatic neurological disorders, the possibility that people with MS 
with asymptomatic evaluation may present abnormal TMS measures exists. Further, 
whether TMS measurements can detect the functional impact of asymptomatic lesions is 
unknown.  
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1.4.5 What we Know Thus Far: TMS in MS  
1.4.5.1  TMS as a Biomarker in MS  
As discussed above, in the field of MS research, TMS has demonstrated 
abnormalities within the CST in patients with MS. Some of these findings include 
increased central motor conduction time (Conte, Lenzi et al., 2009, Conte, Lenzi et al., 
2009), delayed MEP latency (Kale, Agaoglu et al., 2009), increased motor threshold (Neva, 
Lakhani et al., 2016) and prolonged CSP (Tataroglu, Genc et al., 2003). Furthermore, 
researchers have explored TMS as a biomarker of disability and its ability to assess the 
effects of treatment (Fierro, Salemi et al., 2002, Tataroglu, Genc et al., 2003, Chaves, Kelly 
et al., 2019). For example, Tataroglu and colleagues (2003) studied 58 patients with MS 
and found that increased central motor conduction time (the time it takes for the TMS signal 
to be transmitted through the motor pathway to the muscle of interest) predicted increased 
disability using the EDSS (Tataroglu, Genc et al., 2003). In other research, Chaves and 
colleagues (2019) found that in 82 patients with MS, prolonged CSP was indicative of low 
fitness measured by a graded maximal exercise test (Chaves, Kelly et al., 2019). 
Additionally, Fierro and colleagues (2002) assessed the change in motor threshold, central 
motor conduction time and CSP in response to two treatment doses of methylprednisolone 
in 9 patients with relapsing-remitting MS (Fierro, Salemi et al., 2002). They detected an 
improvement (reduction) in CSP with both high and low treatment doses and an 
improvement in motor threshold and central motor conduction time with the highest dose 
of treatment. Overall, research suggests that TMS could be a promising tool to map 
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symptom severity and test the benefits of drug and rehabilitative treatments on motor 
performance.  
 
1.4.5.2 The Importance of TMS as a Biomarker at an Individual Level in MS  
In order for a biomarker such as TMS to be advantageous, it should strongly 
correlate with severity of symptoms in a cohort and at an individual level over time (Woo, 
Chang et al., 2017). To our knowledge, studies which have investigated TMS as a 
biomarker tend to group all patients together and have yet to separate patients by their main 
symptoms which essentially disregards the heterogeneity of MS. Whether TMS could be 
used to distinguish clinical profiles of MS (motor, cognitive, sensory or asymptomatic 
presentation), and whether changes in TMS measures would be associated with symptoms 
of disease severity, is worthy of investigation (Ferreri, Pauri et al., 2003, Ni & Chen, 2015). 
Historically, TMS has been most useful in diseases where there is dysfunction of the CST  
(Cortes, Black-Schaffer et al., 2012). Since TMS primarily assesses the CST, it is plausible 
that TMS may only provide information on brain integrity among people who have motor 
symptoms; failing to detect underlying abnormalities among people who have non-motor 
MS symptoms. This thesis aimed to test the usefulness of TMS as a biomarker in groups 
of people with MS who had differing clinical profiles. 
As an overarching goal, we undertook this study as a first step to understand if TMS 
could be a useful biomarker in MS. We aimed to determine if TMS measures could 
distinguish clinical profiles of MS and if these parameters would align with disease 
severity. We first examined a cohort of people with MS, recruited from an MS clinic who 
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presented with a wide range of EDSS scores. Using the functional profiles within the EDSS 
scoring system, the patients were grouped into clinical profiles (motor, sensory, cognitive 
and asymptomatic). TMS was performed on each brain hemisphere and RMT, AMT and 
CSP data were gathered. Secondly, we aimed to identify if these TMS parameters could 
predict symptom severity (walking speed and cognition) within each clinical profile, with 
better sensitivity than the EDSS. 
 
1.5 SUMMARY 
MS is an unpredictable neurodegenerative disease involving the autoimmune attack 
of myelin within the CNS. The EDSS is the most common tool used to provide people with 
MS a measure of their disease severity; however, because it is an observer-rated categorical 
scale, it has been reported to lack sensitivity, has limited capacity to detect heterogeneity 
and low inter-rater reliability. The need to develop an objective biomarker, more sensitive 
than the current EDSS, is critical and TMS may have the potential to fill this gap. With 
accumulating evidence for abnormal TMS measures in neurological disorders, it is possible 
that TMS measures, specifically RMT, AMT, and CSP, may have the ability to distinguish 
clinical profiles of MS and may further be able to predict symptom disease severity. The 
first objective of this research was to investigate whether TMS measures could differentiate 
between four clinical profiles of MS; motor, sensory, cognitive and asymptomatic groups. 
The second objective was to determine whether TMS measures could predict symptom 
severity measures with better sensitivity than the current disease severity measure, EDSS. 
If TMS proves to be a useful biomarker in the field of MS, its use could facilitate 
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personalized medicine, non-invasively, and relatively inexpensively, tracking the 
progression of the disease and treatment responses on an individual level with greater 
sensitivity than the EDSS. 
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Chapter 2: Methods and Results 
2.1 METHODS 
2.1.1 Participants  
 Persons with MS (n=38) were recruited as part of a longitudinal provincial MS 
database coordinated by the Health Research Innovative Team in MS. Inclusion criteria 
included 1) able to walk at least indoors with or without aid; 2) diagnosed with MS (of any 
type) by a MS neurologist using McDonald criteria (McDonald, Compston et al., 2001); 3) 
18 years or older; 4) able to participate in TMS assessment as per standardized TMS 
screening form (Rossi, Hallett et al., 2009) and 5) at least 3 months relapse-free. 
Demographics collected included age, sex, MS type and disease duration (years) (Table 
2.1).  
 
2.1.2 EDSS Classification  
The MS neurologist provided the EDSS score based on clinical observations of the 
patient in combination with completing the functional system scale which included seven 
domains; pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual and cerebral. 
Patients were scored on each functional system scale domain ranging from 0- 5 or 6 (higher 
scores indicate greater impairment). Four main groups of participants were created based 
on their clinical deficits. Categories included; sensory symptoms (visual, brainstem and 
sensory functions) (n=11), motor symptoms (bowel, bladder, pyramidal and cerebellar 
functions) (n=12), cognitive symptoms (cerebral functions) (n=8) and asymptomatic MS 
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(n=7). Each participant was assigned to one of four clinical groups based on the category 
in which they had the highest score (EDSS functional system score).  
 
  2.1.3 Procedure  
After obtaining consent and gathering demographic information (age, sex, and level 
of education), participants completed the Montreal Cognitive Assessment (MoCA), the 
Symbol Digit Modality Test (SDMT) and the Multiple Sclerosis Impact Scale (MSIS-29) 
(all data collection forms can be accessed in Appendix A). Participants were then asked to 
walk on an instrumented walkway (ProtoKinetic Walkway), followed by TMS.  
 
2.1.3.1 Cognitive Assessments  
The MoCA is a cognitive screening test, developed by Nasreddine and colleagues in 
2005, which assesses eight aspects of cognition including memory, visuospatial abilities, 
and executive function (Nasreddine et al., 2005). Scores range from 0-30. Scores below 26 
indicate mild to moderate cognitive impairment. MoCA has been demonstrated as a reliable 
and valid cognitive screening tool in the MS population (Dagenais, Rouleau et al., 2013). 
The SDMT assesses cognitive function through a simple 90-second substitution task where 
participants substitute numbers for given geometric figures using a reference key. It has 
been validated as a measure of cognitive processing speed among people with MS with a 
value below the cut-off of 40 indicating cognitive impairment (Drake, Weinstock-Guttman 
et al., 2010). Higher scores are indicative of faster cognitive processing speed. 
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2.1.3.2 Walking Assessment  
Participants walked on a 4’ X 14’ instrumented ProtoKinetic walkway in order to 
record an individual’s footfalls (ProtoKinetics Inc, Havertown PA, USA). The 
instrumented walkway records and calculates pressure and spatiotemporal gait 
characteristics through a grid system. The grid system of the ProtoKinetic walkway is 
designed with load cells; thus, when participants walk on the walkway, information about 
the location and number of load cells activated, as well as the force on the load cells is 
transmitted to the computer system (PKMAS software). Variables provided include force 
of foot on the ground, step length, stride length, stride width, and walking velocity.  
In MS research, the instrumented walkway has been demonstrated as a valuable tool 
when evaluating the impact of cognitive tasks on gait parameters (Kirkland, Wallack et al., 
2015). In other MS research, the ProtoKinetic walkway was used to illustrate the use of 
bipedal hopping to predict subtle impairments in lower limb neuromuscular performance 
(Kirkland, Downer et al., 2017). In our study, participants were asked, using a standardized 
script, to walk twice across the walkway at a comfortable self-selected walking pace. The 
participants’ self-selected walking velocity (cm/s) was then calculated by dividing the sum 
of the stride length measurements by the sum of the stride time measurements (provided 
by the PKMAS software). 
 
2.1.3.3 Subjective Impact of MS 
 The MSIS-29 consists of 29 questions that ask about the impact of specific MS 
symptoms on everyday life. It is scored according to a 5-point Likert scale ranging from 1 
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(no impact) to 5 (extremely impacted by MS). Nine questions address the psychological 
impact of MS (score range of 5-45) and 20 questions address the physical impact of MS 
(score range from 20-100) with higher scores indicating a greater perceived impact of MS 
on the individuals’ psychological and physical state (Hobart, Lamping et al., 2001). Some 
of the questions in the MSIS-29 include, “In the past two weeks, how much have you been 
bothered by problems with your balance?” and “In the past two weeks, how much have 
you been bothered by feeling mentally fatigued?”.  The validity and reliability of both the 
physical and psychological subsections of the MSIS-29 have been confirmed (Hobart, 
Lamping et al., 2001).  
 
  2.1.3.4 TMS 
The participant’s brain excitability in each hemisphere was measured by eliciting 
monophasic TMS pulses, using a BiStim 2002 stimulator connected to a figure-of-eight coil 
with an outer diameter of 70mm (Magstim, Co. Whitland UK). To measure 
electromyography (EMG) activity and collect the MEPs, the skin was prepared (Gilmore 
& Meyers, 1983) and foam surface electrodes (Kendall 200 Covidien, Mansfield, MA) 
were placed on the belly of the first dorsal interosseous muscle. The reference electrode 
and ground electrode were placed on the interphalangeal joint of the index finger and the 
styloid process, respectively. A neuronavigation device (Brainsight Rogue Research Inc, 
Montreal, QC, Canada) with a built-in EMG system was used for the collection of MEPs. 
The EMG system uses a 2500V/V amplification and 12-bit resolution analog to digital 
converter, it collects with a sampling rate of 3kHz, 4.5mVpp of the input range, gain of 
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600V/V with a bandwidth of 16-550Hz. A brain template from the Montreal Neurological 
Institute was integrated into the Brainsight software as a 3-dimensional stereotaxic image 
in order to accurately target the region of the motor cortex corresponding to the first dorsal 
interosseous muscle (Collins, Neelin et al., 1994). 
Participants were seated upright, and the coil was held tangentially to the scalp at an 
angle of 45° from the midline. First, suprathreshold stimulations were fired at different 
sites over the primary motor cortex. The area with the highest response in the first dorsal 
interosseous muscle (MEPs peak-to-peak amplitude) was chosen as the hotspot. Secondly, 
motor thresholds were determined as the minimum amount of intensity of the TMS output 
which evoked 5 out of 10 MEPs of ≥ 50μV during muscle relaxation, known as RMT and 
≥ 200μV during 10-15% of first dorsal interosseous maximal voluntary contraction, known 
as AMT (Rossini, Barker et al., 1994; Goss, Hoffman et al., 2012). Motor threshold values 
were reported as percentages of the maximum stimulator output. All MEPs were elicited 
bilaterally, that is, in each hand/brain hemisphere. The CSP was collected from the 5 out 
of 10 successful MEPs of the AMT and averaged over the total CSP’s obtained. The CSP 
duration was defined as the time from the end of the MEP to the return of voluntary EMG 
activity as reported in previous studies (Nakashima, Wang et al., 1995; Modugno, Curra et 
al., 2001; Tataroglu, Genc et al., 2003). 
Since MS lesions are often spread throughout the CNS affecting both cerebral 
hemispheres, we collected TMS in both hands and labeled the hands as ‘stronger’ or 
‘weaker’ based on hand grip and pinch strength measured using a dynamometer (Lafayette 
Instruments, Lafayette, IN, and B&L Engineering, Santa Ana, CA, respectively). 
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Participants performed the hand grip and pinch strength task twice and the average score 
was reported. In MS patients, the side of the body is thought to be the side that is most 
affected (Fritz, Keller et al., 2017), thus, a participant’s weaker side was determined based 
on the hand with the lowest combined grip and pinch strength measures (grip + pinch).  
 
2.1.4 Statistical Methods 
Values of CSP, RMT and AMT between the more affected and less affected 
hemispheres were compared using paired-sample t-tests within the sample as a whole.  
Next, an ANOVA Bonferroni Post Hoc test was used to assess the differences in TMS 
measures between clinical groups. P<0.05 was considered significant. Effect sizes were 
expressed as partial eta squared (ƞ2) where ƞ2 of 0.01 was considered a small effect, 0.06 
a moderate effect, and 0.14 a large effect (Cohen, 1992). Simple linear regression analyses 
were conducted in order to determine whether TMS measures predicted cognitive (MoCA, 
SDMT, MSIS-29 Psychological), or physical (walking velocity, MSIS Physical) outcome 
severity within the clinical profiles. Subsequently, stepwise linear regression was used to 
determine which TMS measures best predicted symptom severity. Each model was 
evaluated by the model R and r2 value. Data were analyzed using IBM SPSS version 23. 
 
2.2 RESULTS 
2.2.1 Participants 
Participants on average were 48.1 (± 9.76) years of age. There were 35 individuals 
with relapsing-remitting MS and 3 with secondary progressive MS. A one-way ANOVA 
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was used to compare patients demographic information including age, EDSS, walking 
velocity, MoCA, SMT, MSIS Physical and MSIS Psychological. When comparing 
disability scores (EDSS), those in the motor group had a higher disability score than those 
in the sensory and asymptomatic groups (Table 2.1). Additionally, those in the cognitive 
group had a greater perceived impact of MS on their psychological state compared to those 
in the asymptomatic group (Table 2.1).  
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TABLE 2.1 PARTICIPANT DEMOGRAPHIC INFORMATION 
Clinical Profile Motor Sensory Cognitive Asymptomatic 
 
Subjects  12 11 8 7 
Age (mean ± SD) 51.8 ± 9.1 44.3 ± 11.1 50.3 ± 8.5 42.3 ± 9.8 
Sex  
     Female/Male 
 
9/3 
 
4/7 
 
6/1 
 
3/4 
Type of MS  
     Secondary Progressive 
     Relapsing-Remitting 
 
2 
10 
 
0 
11 
 
1 
7 
 
0 
7 
EDSS (mean ± SD) 
 
Walking velocity (mean ± 
SD) 
 
MoCA (mean ± SD) 
 
SDMT (mean ± SD) 
 
MSIS Physical (mean ± 
SD) 
 
MSIS Psychological 
(mean ± SD)  
3.4 (± 0.6) 
 
92.9cm/s (± 
25.3) 
 
25.5 (± 3.6) 
  
42.4 (± 12.8) 
  
44.7 (± 17.8) 
  
 
18.5 (± 7.7)  
1.9 (± 0.3)a 
 
112.4cm/s (± 
19.2) 
  
27.1 (± 2.3) 
  
51.8 (± 4.9) 
  
32.4 (± 13.4) 
 
  
14.5 (± 4.4) 
2.2 (± 0.7) 
 
98.8cm/s (± 
25.3) 
  
26.5 (± 4.8) 
  
50.0 (±3.1) 
  
47.9 (± 20.8) 
  
 
24.3 (± 8.6) 
0b 
 
107.1cm/s (± 
14.7) 
  
25.6 (± 3.9) 
 
47.9 (± 12.9) 
  
28.9 (± 10.2) 
 
  
17.8 (± 7.4)c 
EDSS: Expanded Disability Status Scale 
MoCA: Montreal Cognitive Assessment 
SDMT: Symbol Digit Modality Test 
MSIS: Multiple Sclerosis Impact Scale 
± Denotes the standard error value 
a Denotes a statistical significance from the motor group p<0.05 
b Denotes a statistical significance from the motor group p<0.001 
c Denotes a statistical significance from the cognitive group p<0.05 
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2.2.2 Differences in TMS measures between brain hemispheres 
There was a difference of hemisphere on RMT (t(35) = -3.387, p < 0.001,), AMT (t(36) 
= -4.654, p < 0.001) and CSP ( t(35) = -2.175, p < 0.001). As expected, the RMT was higher 
in the hemisphere corresponding to the weaker hand (45.83% ± 12.01) compared to that of 
the stronger hand (41.24% ± 10.37) in all clinical groups. The AMT was also higher in the 
hemisphere corresponding to the weaker hand (40.00% ± 13.24) than the stronger hand 
(34.05% ± 8.81). Additionally, the CSP was longer in the hemisphere corresponding to the 
weaker hand (33.49ms ± 18.12) than the stronger hand (26.72ms ± 12.74) (Figure 2.1).  
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FIGURE 2.1: TMS DETECTED HEMISPHERIC DIFFERENCES IN MS 
PARTICIPANTS  
(A) MS participants show a higher mean resting motor threshold (RMT) in the hemisphere 
corresponding to the weaker hand (more affected side) than the stronger hand (less affected 
side) (B) MS participants show a higher mean active motor threshold (AMT) in the 
hemisphere corresponding to the weaker hand (more affected side) than the stronger hand 
(less affected side) (C) MS participants show a higher mean cortical silent period (CSP) in 
the hemisphere corresponding to the weaker hand than the stronger hand. * (p<0.01), error 
bars are SEM 
 
 
 
 
 
 
 
 
 
 
 
Side Side Side 
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2.2.3 Differences in TMS measures between clinical groups 
There was an interaction effect of clinical group and hemisphere on CSP (F(1,32) = 
4.45, p = 0.010, np2  = 0.29), however; there was no interaction for RMT (F(1,32) = 0.50, p = 
0.695, np2  =  0.05) and AMT (F(1,32) = 1.58, p = 0.214, np2  = 0.13). Both of these non-
significant interactions approach moderate and large effective sizes. This is suggestive that 
these sample sizes may not be large enough to detect a statistical significance and should 
be considered when interpreting these results.   
 In the hemisphere corresponding to the stronger hand, participants with motor 
impairments had a significantly longer CSP ([F (3,33) = 3.87, p = 0.018] 35.65ms ± 16.64) 
than those with sensory impairments (20.52ms ± 5.07). The CSP of the hemisphere 
corresponding to the stronger hand was not different between the remaining clinical groups 
(Figure 2.2). In the hemisphere corresponding to the weaker hand, participants with motor 
impairments had significantly longer CSP (51.65ms ± 20.40 [F(3,33) = 8.965, p < 0.001]) 
than those with sensory impairments (24.14ms ± 5.15), cognitive impairments (29.40ms ± 
14.71) and those who were asymptomatic (25.33ms ± 9.76) (Figure 2.2).   
 As there were no differences in RMT and AMT between brain hemispheres, the 
hemisphere values were averaged for subsequent analyses. RMT for the motor group 
(51.04% ± 12.73 [F (3,37) = 38.60, p < 0.001) was significantly higher compared to that of 
the sensory group (34.77% ± 4.35) and those who were asymptomatic (39.86% ± 1.99). 
The RMT of the cognitive group (47.81% ± 6.85) was significantly higher than the sensory 
group (Figure 2.3).  
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FIGURE 2.2: THE DIFFERENCE IN CSP BETWEEN CLINICAL MS PROFILES 
The CSP (cortical silent period) of the hemisphere corresponding to the stronger hand (less 
affected side) was longer in individuals with motor impairments than those with sensory 
impairments. The CSP of the hemisphere corresponding to the weaker hand (more affected 
side) was longer in individuals with motor impairments than those with sensory 
impairments, cognitive impairments and those who are asymptomatic. # indicates a 
statistically significant difference from the sensory group (p<0.01). * indicates a 
statistically significant from all clinical groups (p<0.01). Error bars represent standard error 
of the mean. 
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FIGURE 2.3: THE DIFFERENCE IN RMT AND AMT BETWEEN CLINICAL MS 
PROFILES  
(A) The mean RMT (resting motor threshold) was higher in individuals with motor 
impairments than those with sensory impairments and those who are asymptomatic. The 
RMT of the cognitive group was significantly higher than the sensory group. (B) The mean 
AMT (active motor threshold) of the motor group was significantly higher than those in 
the sensory, cognitive and asymptomatic group. * indicates a statistically significant 
difference from the sensory and asymptomatic groups.  # indicates a statistically significant 
difference from the sensory group (p<0.01). ¥ indicates a statistically significant difference 
from the sensory group (p<0.01) 
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In terms of AMT values, only the AMT of the motor group (43.95% ± 11.23 [F (3,34) 
= 5.79 p = 0.003]) was significantly higher than sensory group (29.64% ± 3.89). However, 
there were no significant differences between the motor group and the asymptomatic 
(32.86% ± 3.18) and cognitive groups (40.06% ± 12.48). There were also no significant 
differences between the three non-motor groups (Figure 2.3).  
 
2.2.4 Relationship between symptom severity and TMS Measures 
Since the TMS results suggested that there were more robust changes in the 
hemisphere corresponding to the weaker hand and previous studies in stroke and MS have 
confirmed that TMS changes primarily in that hemisphere (Beaulieu & Milot, 2018); we 
chose to complete simple linear regression on values collected from that side. We found 
that CSP and AMT most consistently predicted physical and cognitive symptom severity 
for the motor and cognitive groups but not for the sensory and asymptomatic groups (Table 
2.2 and 2.3). For example, in the motor group, CSP predicted 64% of variance in walking 
velocity and 61% and 91% of variance for the subjective physical and psychological impact 
scores of MS (MSIS-29) respectively. CSP provided no predictive value of the severity of 
physical or cognitive symptoms in the sensory or asymptomatic clinical groups. Overall, 
CSP provided stronger predictive value and was more consistent than AMT.  
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TABLE 2.2 RELATIONSHIP BETWEEN SYMPTOM SEVERITY MEASURES 
AND CSP OF THE WEAKER SIDE FOR CLINICAL MS PROFILES  
Clinical Indicators of MS F statistic p-Value R2 
Motor Group  
Cognitive Variables 
• MoCA 
• SDMT 
• MSIS Psychological 
 
Motor Variables 
• Mean Velocity 
• MSIS Physical 
 
1.559 
1.593 
13.965 
 
 
15.879 
87.372 
 
0.243 
0.239 
0.005 
 
 
0.003 
0.000006 
 
0.053 
0.150 
0.608* 
 
 
0.638* 
0.907* 
Sensory Group 
Cognitive Variables 
• MoCA 
• SDMT 
• MSIS Psychological 
 
Motor Variables 
• Mean Velocity 
• MSIS Physical 
 
0.002 
1.079 
0.675 
 
 
5.062 
0.385 
 
0.965 
0.329 
0.433 
 
 
0.051 
0.550 
 
0.000 
0.009 
0.070 
 
 
0.360 
0.041 
Cognitive Group 
Cognitive Variables 
• MoCA 
• SDMT 
• MSIS Psychological 
 
Motor Variables 
• Mean Velocity 
• MSIS Physical 
 
6.499 
18.608 
0.841 
 
 
17.939 
1.384 
 
0.044 
0.005 
0.394 
 
 
0.008 
0.284 
 
0.520* 
0.716* 
0.123 
 
 
0.738* 
0.052 
Asymptomatic Group 
Cognitive Variables 
• MoCA 
• SDMT 
• MSIS Psychological 
 
 
0.393 
0.034 
0.559 
 
 
0.558 
0.665 
0.488 
 
 
0.073 
0.040 
0.101 
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Motor Variables 
• Mean Velocity 
• MSIS Physical 
 
0.211 
0.962 
 
0.003 
0.372 
 
0.040 
0.161 
*Statistical significance (p<0.05) 
CSP- Cortical Silent Period 
MoCA- Montreal Cognitive Assessment 
SDMT- Symbol Digit Modality Test 
MSIS- Multiple Sclerosis Impact Scale  
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TABLE 2.3: RELATIONSHIPS BETWEEN SYMPTOM SEVERITY MEASURES 
AND MOTOR THRESHOLDS OF THE WEAKER SIDE FOR CLINICAL MS 
PROFILES 
 
RMT AMT 
 
Clinical Indicators 
of MS 
 
F 
statistic 
 
p-
Value 
 
R2 
 
F 
statistic 
 
p-Value 
 
R2 
Motor Group 
Cognitive Variables 
• MoCA 
• SDMT 
• MSIS 
Psychological 
 
Motor Variables 
• Mean Velocity 
• MSIS Physical 
 
6.849 
1.819 
2.253 
 
 
 
2.840 
5.579 
 
0.026 
0.207 
0.164 
 
 
 
0.123 
0.040 
 
0.347* 
0.154 
0.184 
 
 
 
0.221 
0.358* 
 
7.006 
2.636 
5.022 
 
 
 
9.479 
23.553 
 
0.024 
0.136 
0.049 
 
 
 
0.012 
0.001 
 
0.412* 
0.209 
0.334* 
 
 
 
0.487* 
0.702* 
Sensory Group 
Cognitive Variables 
• MoCA 
• SDMT 
• MSIS 
Psychological 
 
Motor Variables 
• Mean Velocity 
• MSIS Physical 
 
0.817 
3.138 
2.253 
 
 
 
0.058 
0.640 
 
0.392 
0.114 
0.164 
 
 
 
0.815 
0.444 
 
0.093 
0.282 
0.184 
 
 
 
0.006 
0.066 
 
0.001 
2.486 
2.178 
 
 
 
2.137 
0.506 
 
0.971 
0.154 
0.174 
 
 
 
0.178 
0.495 
 
0.0002 
0.237 
0.195 
 
 
 
0.192 
0.053 
Cognitive Group 
Cognitive Variables 
• MoCA 
• SDMT 
• MSIS 
Psychological 
 
Motor Variables 
 
9.350 
1.590 
0.977 
 
 
 
1.089 
 
0.022 
0.254 
0.361 
 
 
 
0.345 
 
38.721* 
4.074 
0.689 
 
 
 
5.969 
 
38.721 
4.074 
0.689 
 
 
 
5.969 
 
0.001 
0.090 
0.438 
 
 
 
0.058 
 
0.866* 
0.404 
0.103 
 
 
 
0.544 
 53 
• Mean 
Velocity 
• MSIS 
Physical  
5.628  0.055  11.473  11.473  0.015  0.657*  
Asymptomatic Group 
Cognitive Variables 
• MoCA 
• SDMT  
• MSIS 
Psychological 
 
Motor Variables 
• Mean Velocity 
• MSIS Physical 
 
0.151 
1.422 
0.734 
 
 
 
0.495 
0.719  
 
0.714 
0.287 
0.431 
 
 
 
0.513 
0.435  
 
0.171 
0.221 
0.128 
 
 
 
0.090 
0.126  
 
0.773 
0.005 
0.998 
 
 
 
0.757 
1.287  
 
0.419 
0.948 
0.364 
 
 
 
0.424 
0.308  
 
0.134 
0.001 
0.166 
 
 
 
0.131 
0.205  
*Statistical significance (p<0.05) 
AMT- Active Motor Threshold 
RMT- Resting Motor Threshold  
MoCA- Montreal Cognitive Assessment 
SDMT- Symbol Digit Modality Test 
MSIS- Multiple Sclerosis Impact Scale  
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2.2.5 Comparison of TMS and EDSS to Predict Symptom Severity in MS  
To determine whether TMS measures predicted symptom severity compared to the 
EDSS, all TMS measures and EDSS were included as predictors of physical and cognitive 
symptoms for the four clinical groups.  Since previous simple linear regressions determined 
that CSP and AMT were able to predict several symptom severity measures only for the 
motor and cognitive groups but not for the sensory and asymptomatic groups, the clinical 
groups were combined into two subgroups (motor/cognitive and sensory/asymptomatic) 
for step-wise linear regression analysis.   
A stepwise regression was calculated to predict symptom severity measures based 
on EDSS and TMS measures. The EDSS was entered into the model first (Dependent 
Variable=EDSS + Error) to model 2 (Dependent Variable= EDSS + CSP + AMT + RMT 
+ Error). When assessing predictors of walking velocity, EDSS was not a significant 
predictor. After entering significant TMS predictors as well as EDSS into the model, for 
the motor and cognitive group, CSP (not RMT, AMT or EDSS) was the only predictor 
of walking velocity and accounted for 59% of the variance (F (1,16) = 22.82, p < 0.001) 
(Figure 2.4). For every 1ms increase in CSP the walking velocity decreased by 0.95cm/s. 
Figure 2.4 illustrates walking speeds and CSP in two representative EMG outputs of 
participants with the same EDSS. There were no TMS predictors of walking speed 
identified for the sensory and asymptomatic combined group (data not shown) 
When assessing predictors of the subjective physical impact score, EDSS was not 
a significant predictor when added to the model by itself. After adding CSP, RMT and 
AMT to the model, the AMT was the only predictor of subjective physical impact of MS 
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score, accounting for 64% of its variance (F (1,17) = 30.63, p < 0.001) in the motor/cognitive 
combined group (Figure 2.4). The subjective physical impact score of MS increased by 
1.31 points for every 1% increase in AMT (maximal stimulator output percentage). In 
addition, the EDSS model was not predictive of cognitive impairment (MoCA).  When 
TMS measures were added in the second model, AMT was found to be the only predictor 
of MoCA, accounting for 60% of its variance (F (1,17) = 30.63, p < 0.001). The MoCA score 
decreased by 0.24 points for every 1% increase in AMT (maximal stimulator output 
percentage) (Figure. 2.4 and Table 2.4). There were no TMS predictors of MSIS-29 
(physical or psychological) identified for the sensory and asymptomatic group (data not 
shown). 
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TABLE 2.4 SUMMARY OF STEPWISE REGRESSION ANALYSES FOR 
PREDICTORS OF SYMPTOM SEVERITY FOR MOTOR AND COGNITIVE MS 
GROUPS 
Motor and Cognitive Group 
 
Clinical Indicator   
 
Model 
Components 
 
p 
 
R2 
 
β 
Mean Velocity CSP  0.000206 0.588 -.950 
MSIS Physical AMT  0.000036 0.643 1.306 
MoCA AMT  0.000103 0.598 -0.244 
SDMT -  - - - 
MSIS 
Psychological 
- - - - 
AMT- Active Motor Threshold 
CSP- Cortical Silent Period 
MoCA- Montreal Cognitive Assessment 
SDMT- Symbol Digit Modality Test 
MSIS- Multiple Sclerosis Impact Scale 
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FIGURE 2.4: THE RELATIONSHIP BETWEEN TMS MEASURES AND 
SYMPTOMS OF DISEASE SEVERITY FOR PEOPLE WITH MS WITH MOTOR  
AND COGNITIVE PROFILES  
A) Cortical silent period (CSP) significantly predicts participant’s mean walking velocity 
(p<0.001). B) Active motor threshold (AMT) significantly predicts cognitive impairment 
(Montreal Cognitive Assessment (MoCA)) (p<0.001). C) Active motor threshold (AMT) 
significantly predicts participant’s score of perceived physical impact of MS (MSIS-29) 
(p<0.001).  
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FIG 2.5: REPRESENTATIVE CSP OF TWO PARTICIPANTS WITH THE SAME 
EDSS SCORE 
A) 62 year-old female with primary motor symptoms, a walking speed of 101.0cm/s and a 
CSP (cortical silent period) of 36.2ms B) 40 year old female with primary cognitive 
symptoms, a walking speed of 75.6cm/s and a CSP of 63.4ms. EDSS: Expanded Disability 
Status Scale 
 
 
Figure 2.5 illustrates how patients in the motor and cognitive profile groups with the same 
EDSS score had substantially different CSP and AMT values. For example, although 
scoring the same on the EDSS (Score of 2), one patient had an AMT value of 25% 
maximum stimulator output and the other with a value of 42% maximum stimulator output.     
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FIG 2.6: CSP AND AMT DETECT CHANGES IN PEOPLE WITH MS WITH THE 
SAME EDSS 
The relationship between the length of the CSP (cortical silent period), the AMT (active 
motor threshold) and the expanded status disability scale (EDSS) scores for individuals 
with MS who displayed motor symptoms and cognitive symptoms. %MSO: Percentage of 
maximum stimulator output. 
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Chapter 3: Discussion 
  3.1 OVERVIEW  
The research outlined in this thesis examined the use of TMS measures as a 
biomarker of symptom severity in MS. There were two main objectives of this thesis. The 
first objective was to investigate whether TMS measures could differentiate four clinical 
profiles of MS; motor, sensory, cognitive and asymptomatic groups. Among 38 people 
with MS, we found that the TMS measure, AMT was significantly higher and the TMS 
measure, CSP was significantly prolonged in the hemisphere corresponding to the weaker 
hand of the motor group, compared to the other clinical profiles of MS. This finding 
suggested that TMS may be more useful as a biomarker among people who have 
primarily motor symptoms. The second objective was to determine whether TMS 
measures could predict symptom severity measures with better sensitivity than the 
current disease severity measure, EDSS. All four clinical groups were included in this 
second analysis for exploratory purposes. TMS measures were found to predict symptom 
severity measures for both the motor and cognitive groups of MS; thus, these groups 
were combined for further analysis. In the motor and cognitive group (n=20), CSP was 
the strongest predictor of walking speed with a prolonged CSP indicating a slower 
walking speed. CSP is an indicator of the degree of motor cortical inhibition with higher 
levels of corticospinal inhibition being found to correlate with reduced capacity for 
neuroplasticity (Jurado-Parras, Delgado-García et al., 2016). Additionally, in the motor 
and cognitive group, AMT was the strongest predictor of cognitive impairment measured 
by the MoCA and perceived physical impact of MS measured by the MSIS-29. A higher 
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AMT predicted a lower score on the MoCA and greater perceived physical impact of MS 
using the patient-reported MSIS-29. Overall, EDSS was not predictive of symptom 
severity measures for the motor and cognitive group. Among participants in the sensory 
and asymptomatic clinical groups, none of the TMS measures or EDSS predicted 
symptom severity (motor or cognitive performance or subjective health).  
 In this chapter, two major findings will be highlighted including CSP as a 
predictor of walking symptom severity (motor and cognitive group) and AMT as a 
predictor of cognitive symptom severity (motor and cognitive group). Secondly, we will 
discuss the implications for individual profiles of MS (motor, cognitive, sensory and 
asymptomatic). Lastly, we will explore how this study could be used to guide the 
development of future clinical measurement tools to advance the field of MS 
rehabilitation research.  
 
3.2 TMS AS A BIOMARKER OF SYMPTOM SEVERITY  
3.2.1 Walking Ability is Best Predicted by CSP in People with Motor and Cognitive 
MS Profiles  
Walking is an important clinical marker of disease progression in MS. Our 
findings demonstrated that specific TMS measure, CSP, could be a biomarker of walking 
ability, and by extension, disability progression. The average mean walking speed of 
healthy adults up to the age of 59 is approximately 140cm/s (Bohannon & Andrews, 
2011) and decreases over time to approximately 95cm/s in individuals over the age of 80 
(Pirker & Katzenschlager, 2017).  In our study, the walking speeds of individuals with 
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motor and cognitive symptoms were 92.9cm/s and 98.8cm/s respectively. While these 
groups were on average 50 years of age, their walking speed was comparable to a healthy 
individual at least 30 years older (Pirker & Katzenschlager, 2017). Furthermore, we 
showed that for every 1ms increase in CSP, walking velocity decreased by 0.95cm/s in 
the motor and cognitive subgroups. The value of CSP as a potential biomarker is not 
exclusive to this study and has been suggested to be an important predictor of motor 
function through work in the field of other neurological disorders, such as stroke (Gray, 
Palmer et al., 2017). For instance, Gray and colleagues (2017) reported a relationship 
between prolonged CSP and increased motor impairment (Wolf Motor Function Test task 
completion time) among 13 people with stroke. In a study examining the effects of wrist 
extensor muscle training on CSP in people with chronic stroke, Sun et al reported that 
CSP significantly decreased after training (Sun, Ledwell, Boyd & Zehr, 2018). 
Additionally, among people with MS, shorter CSP correlated with less cortical damage 
measured using MRI (Nantes, Zhong et al., 2016). Overall, our study results align with 
those that indicate the importance of CSP as a possible biomarker of motor function.  
 
3.2.2 CSP as a Biomarker of Walking Ability in a Clinical Setting 
In MS, problems with walking are one of the most common and burdensome 
deficits (LaRocca, 2011). MS studies report that difficulties with walking are linked to 
fall risk (Matsuda, Shumway-Cook et al., 2012) and an increased need for healthcare 
usage which contributes to economic burden and decreased quality of life (Pike, Jones et 
al., 2012). In our study, it was interesting to detect that while CSP was a significant 
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predictor of walking speed for the motor and cognitive group, EDSS was not predictive at 
all. Visual inspection of gait (as assessed in EDSS) is not as sensitive compared to 
measurements using sophisticated methods such as kinetics such as that used within an 
instrumented walkway. For instance, Goodkin and colleagues (1992), found that the 
EDSS was insensitive to disease progression in the lower ranges, from 1.0-3.5, when 
walking deficits are likely more subtle (Goodkin, Cookfair et al., 1992). Furthermore, 
more recent research by Galea and colleagues (2017) showed that EDSS was insensitive 
to gait and balance changes over a 12-month period in 38 people with MS with an EDSS 
score ≤ 3 (Galea, Cofré Lizama, Butzkueven & Kilpatrick, 2017). Early identification of 
deterioration is important in order for clinicians to quickly adapt the treatment regime. 
Our results support that TMS is useful in detecting small differences in walking quality. 
TMS out-performed EDSS suggesting that by the time individuals with MS begin to 
display lower EDSS scores, they likely have accumulated substantial disability. In this 
study, CSP predicted walking disability in a cross-sectional cohort. It would be important 
to examine CSP longitudinally in order to determine whether this TMS measure changes 
over time at an individual level. Earlier detection of walking decline could potentially 
help develop and monitor a personal plan to prevent risks of falls, injuries, further decline 
and in turn, improve quality of life.  
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3.2.3 AMT is Predictive of Cognitive Impairment for People with Motor and 
Cognitive Profiles of MS  
In our study, we discovered that higher AMT thresholds were predictive of lower 
MoCA scores (a cognitive screening tool) for the motor and cognitive groups, however, 
AMT was not predictive of the SDMT, another cognitive test of processing speed. This 
result differs from our previous work by Chaves and colleagues (2019), who found that in 
a cohort of 82 patients with MS, lower AMT in the hemisphere corresponding to the 
patient’s weaker side (determined by pinch and grip strength) was associated with greater 
cognitive impairment measured using the SDMT (Chaves, Kelly et al., 2019). The two 
tools, MoCA and SDMT, measure different constructs and they have different 
administration and scoring properties. MoCA includes 11 items (eg. visuoconstructional 
ability, recall) and provides an indication of overall global cognitive ability whereas 
SDMT has only one task that tracks specifically processing speed. Notably, our cohort 
scored relatively high on the SDMT, with an average score well above the cut off of 40, 
suggesting only mild processing speed challenges. The MoCA scores were, on average, 
at or near in the impaired range (<26).  Our sample size was also small (n=20) compared 
to the cohort examined by Chaves and colleagues (2019) and may not have been large 
enough.  However, the links between AMT and cognitive functioning using two 
measurement methods in two different studies suggest that TMS does indeed correlate 
with cognitive screening tests, which is surprising considering that cognition does not 
typically involve the CST. It is possible that the integrity of the CST is indicative of 
overall corticospinal tract integrity or that TMS is actually measuring the motor aspects 
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of the cognitive test (drawing a figure or writing an answer). Future research should use 
cognitive tests that do not require a motor component in order to decipher whether TMS 
is associated with impairments that are cognitive rather than motor.  
 
3.2.4 Is AMT a Potential Biomarker of Cognitive Impairment in MS in a Clinical 
Setting? 
Statistics show that approximately 40-65% of people with MS, experience cognitive 
symptoms to varying extents (Jongen, Ter Horst et al., 2012), yet, these declines are often 
overlooked and have been labelled the ‘forgotten disability’ (Rahn, Slusher et al., 2012). 
Cognitive decline reduces quality of life, related to activities of daily living and 
negatively impacts social involvement (Baumstarck-Barrau, Simeoni et al., 2011). 
Although measurement of cognitive impairment in MS has improved with the inclusion 
of the SDMT in the MS Functional Composite Measure (Brenton et al., 2019), the 
development of treatments targeting cognitive impairment in MS is only in its 
preliminary stages (Amato, Zipoli et al., 2006). For instance, Chan and colleagues (2017) 
published a phase II study reported that high-dose of the medication, simvastatin, was 
associated with an improvement in the Frontal Assessment Battery (a measure of 
cognitive executive function) compared to placebo-treated groups (Chan, Binks et al., 
2017). Using TMS as a biomarker in a study such as this one would help uncover how 
exactly such a treatment works to enhance cognition. Since cognitive impairment has 
been related to thalamic and basal ganglia atrophy, which occurs later in MS (Batista, 
Zivadinov et al., 2012), TMS may be able to detect changes in these deep structures that 
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have important contributions to motor outputs. Researchers investigating TMS in 
Parkinson’s disease, proposed that TMS has the ability to detect disruption between 
thalamocortical connections, resulting in a disinhibition of the motor cortex and thus, 
indicated by a decrease in motor cortical inhibition (Ridding et al., 1995; Seiss & 
Praamstra, 2004). The results of the research in this thesis supports that the TMS 
measure, AMT, could be useful in a clinical setting, not only to track cognitive changes 
but to test the effectiveness of new pharmaceutical and cognitive rehabilitation treatments 
in those with motor and cognitive profiles of MS. In summary, the discovery of a tool 
that tracks cognitive dysfunction in MS is imperative because maintaining cognitive 
reserve is a way to combat disease progression (Sumowski, Rocca et al., 2013). Future 
studies should investigate whether AMT accurately tracks treatment-induced changes in 
cognition which could potentially prompt quicker and more personalized therapy.  
 
3.3 TAKING A STEP BACK: TMS IS LESS USEFUL FOR SENSORY AND 
ASYMPTOMATIC PROFILES OF MS  
 Indeed, MS is a very complex neurological disorder, with heterogeneity of lesion 
location and different patterns of neurodegeneration. Such heterogeneity means that some 
patients have problems with walking, others with cognition, and some with autonomic 
problems or any combination of these. It is quite plausible that no single biomarker or test 
will be able to track neurophysiological underpinnings of MS symptom severity.  A suite 
of biomarkers of disability may be necessary depending on an individual's symptom 
profile. From our results, it appears that TMS was useful for people with MS who had 
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primarily motor and cognitive symptom profiles and was not as useful for those with 
sensory and asymptomatic profiles. It is important to consider that patients in this study 
were categorized by their “primary” symptom and actually experienced mixed deficits. In 
future, examining the relationship between TMS measures and scores of sensory 
impairments may help elucidate a relationship, if one exists.  
 
3.3.1 TMS May Help Identify Cerebellar Impairment 
3.3.1.1 TMS Predicts Symptom Severity for People with Cerebellar Symptoms of 
MS 
In our sample of people with motor symptoms (n=12), six people had primarily 
pyramidal involvement while six experienced a combination of both pyramidal and 
cerebellar symptoms determined by the neurologist’s assessment of the Kurtzke 
functional system score. We found that the TMS biomarker CSP was sensitive to changes 
in walking ability regardless of whether motor impairments were due to paralysis 
(pyramidal) or incoordination (cerebellar). In accordance with our findings, Tataroglu 
and colleagues (2003) reported significantly prolonged CSP in 12 of 15 people with MS 
with cerebellar symptoms compared to patients with MS without cerebellar symptoms 
(Tataroglu, Genc et al., 2003). On the basis of this finding, the researchers suggested that 
impairments could be attributed to the disruption in the circuitry loop from the 
cerebellum to the motor cortex, known as the cerebello-thalamo-cerebral loop. Although 
the participants in the motor group in the study outlined in this thesis had mixed 
pyramidal and cerebellar findings, distinguishing between the two types of impairment 
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could help inform and track treatments that are targeted for one or the other. Future 
research should confirm the usefulness of TMS as a potential recovery (or progression) 
biomarker for those with cerebellar symptoms. As a first step, it would be important to 
determine whether TMS measures could detect subtle changes in balance and 
coordination such as center of pressure sway or finger/foot tapping tests.  
 
3.3.2 Do TMS Parameters Predict Disease Severity Among People with Exclusive 
Cognitive Profiles of MS? 
To recapitulate our findings, for those with MS with primary cognitive symptoms, 
CSP was the strongest significant predictor of walking velocity and AMT was the 
strongest significant predictor of cognitive impairment (MoCA) and perceived physical 
impact of MS (MSIS-29). It is quite probable that in our study, TMS detected widespread 
cortical dysfunction rather than cognitive impairment per se. We observed that most 
patients experienced more than one type of symptom concurrently. For instance, in our 
cognitive profile group, 5 of 8 people displayed varying levels of underlying pyramidal 
impairment. Other groups have reported that cognitive and physical dysfunction are 
closely linked. Ruano and colleagues (2017) investigated determinants of cognitive 
impairment in 1040 patients with MS and discovered a significant association between 
the increasing degree of cognitive impairment (Brief Repeatable Battery, Stroop Test) 
and greater physical impairment (EDSS) (Ruano, Portaccio et al., 2017). Interestingly, 
disease subtype (relapsing-remitting or progressive) and duration did not predict 
cognition. Although challenging, future research should attempt to recruit people who 
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have fewer overlapping symptoms in order to better understand the use of TMS as a 
predictor of symptom severity for those with cognitive impairment.  
  
3.3.2.1 TMS May be Detecting Subtle CST Abnormalities in Cognitive MS 
Profiles  
Although the majority of our subjects had mixed symptoms, three experienced 
exclusively cognitive impairment. When examining these three subjects in more detail, 
longer CSP was associated with slower walking speed, similar to the rest of the group. 
For example, the CSPs of these three individuals were 16.78ms, 29.09ms and 61.08ms, 
and their walking speeds were 112cm/s, 104.86cm/s, and 49.21cm/s respectively (Figure 
3.1).  Of interest, the third patient’s walking speed was only 30% of typical walking 
speed (120cm/s). It is possible that the neurologist did not report or detect slow walking 
speed in this patient. A major limitation of the study was that we were reliant on the 
neurologist’s ratings in order to classify patients into symptom profile groups. 
Nonetheless, the neurological exam is the cornerstone and main outcome measures in 
many clinical trials of MS treatments. (Uitdehaag, 2014) The fact that the TMS measure, 
CSP, was a better predictor overall that the neurologist-reported EDSS suggests that CSP 
detected subtle abnormalities within the CST that were not detectable when assessed by 
the neurologist. Similarly, Kale and colleagues (2009) found that in 51 patients with no 
pyramidal symptoms (noted by the patient’s neurologic evaluation), TMS abnormalities 
were still detected. For instance, 67% of these patients displayed amplitude abnormality 
(Kale, Agaoglu et al., 2009). Thus, aligning with our results, Kale and colleagues (2009) 
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suggested that TMS detected possible underlying subclinical involvement within the 
CST. Future studies should investigate the use of MRI in addition to this TMS protocol, 
which would allow for the visual detection of potential underlying lesions within the CST 
and matching brain structure with brain function.  
 
3.3.3 TMS is Not a Suitable Biomarker for Sensory and Asymptomatic MS Profiles  
Some people with MS experience pain, numbness and tingling as their primary 
symptoms while others have no detectable symptoms at the time of testing. We 
categorized these clinical profiles into sensory and asymptomatic groups, respectively. 
Our data revealed that CSP and AMT were not useful predictors of the symptom severity 
(walking speed, MoCA, MSIS-29 (Physical)) measures for those with sensory symptoms 
and asymptomatic profiles of MS likely because they may have minimal CST damage. 
Reasonably, TMS is a measure of the integrity of the CST and thus may not predict 
symptom severity that is due to damage of other networks outside the motor system. The 
inability for TMS to predict symptom severity within these profiles highlights the need to 
explore other outcome measures that evaluate areas of the brain involved in sensory and 
asymptomatic MS such as MRI, functional MRI and diffusion tensor imaging.  
 
3.3.3.1 The Next Generation of Biomarkers: Imaging of Both Brain Structure and 
Function  
As discussed, TMS primarily assesses the function of the CST. Other tools such as 
MRI, on the other hand, provide a better assessment of CNS structure. In fact, the two 
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modalities, TMS and MRI, could be considered complementary to one another. Although 
MRI is considered the gold standard for monitoring MS, studies have provided evidence 
pointing to its weak correlation with clinical disability (Li, Held et al., 2006). Li and 
colleagues (2006) gathered a subsample of 1,312 MS patients from 11 randomized 
control trials to examine the relationship between conventional MRI (proton density/T2 
weighted burden of disease) and clinical disability using the EDSS (Li, Held et al., 2006). 
The results indicated a significant but weak to moderate association with degree of 
disability; despite this, this study took place in 2006; hence, MRI techniques were not as 
advanced. Since this time, the implementation of the 7 Tesla MRI now has the ability to 
uncover grey matter pathology and previously undiscovered cortical lesions  (Vigeveno, 
Wiebenga et al., 2012; Kilsdonk, Jonkman et al., 2016). It is important to mention the 
increasing use of multi-modal imaging techniques with MRI (using multiple methods at 
the same time) in MS research. With the use of multimodal imaging, Tewearie and 
colleagues (2014) were able to identify that thalamic atrophy (measured by MRI), was 
associated with disruption of cortical functional networks in MS (measured by 
magnetoencephalography), which was additionally related to worse cognitive and 
physical disability (Tewarie et al., 2014). Thus, utilization of advanced techniques and 
multi-modal neuroimaging will allow for the interplay between structure and function in 
the assessment of disease severity and will aid in the search for personalized biomarkers 
within symptom profiles of MS.   
Diffusion tensor imaging is an  advanced MRI-based neuroimaging technique that 
detects movement of water molecules within the brain thereby providing a measure of the 
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integrity of the myelin sheaths and cell membranes (Pokryszko-Dragan, Banaszek et al., 
2018). This detailed evaluation of tissue microarchitecture with the use of tissue water 
diffusion rates localizes even the smallest lesions within white matter tracts (Soares, 
Marques et al., 2013). Recent studies have demonstrated the clinical relevance of 
diffusion tensor imaging for those with subtle CNS damage in MS. Gratsias and 
colleagues (2015) studied 84 patients with MS and found that diffusion tensor imaging 
detected subtle white matter damage in the early stages of MS (average disease duration 
of 5.6 years) and further determined that greater degeneration in white matter 
significantly correlated with greater clinical disability (EDSS) (Gratsias, Kapsalaki et al., 
2015). Therefore, diffusion tensor imaging may have the ability to detect very subtle and 
minuscule changes in white matter tracts for those with asymptomatic MS who lack 
clinical symptoms yet have accumulating lesion load. Diffusion tensor imaging may also 
be a useful biomarker of disability among people with primarily sensory MS symptoms. 
Pokryszko-Dragan and colleagues (2018) studied 50 patients with relapsing-remitting MS  
and reported that diffusion tensor imaging parameters detected areas of damage within 
the thalamus (Pokryszko-Dragan, Banaszek et al., 2018); an important deep subcortical 
structure containing major sensory nuclei (Baron, Binder et al., 2010). The search for 
optimal brain imaging techniques that provide accurate and sensitive measurement of 
disease progression among those with sensory and asymptomatic profiles of MS is 
ongoing. 
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3.4 OTHER TMS PARAMETERS AS POTENTIAL BIOMARKERS IN MS 
Outside of the TMS measures discussed in this thesis, there are other TMS 
parameters that are used in MS research to provide information regarding activity and 
brain function including axonal, excitatory or inhibitory synaptic excitability in distinct 
neuronal networks  (Tataroglu, Genc et al., 2003; Sahota, Prabhakar et al., 2005; Conte, 
Lenzi et al., 2009; Nantes, Zhong et al., 2016). All of these TMS measures have one 
commonality; the ability to identify the integrity of the corticospinal tract. In addition to 
the AMT and CSP, abnormalities in other TMS parameters such as central motor 
conduction time, short-interval intracortical inhibition and long-interval intracortical 
inhibition have been identified as predictors of clinical disability in MS (Tataroglu, Genc 
et al., 2003; Conte, Lenzi et al., 2009; Vucic, Burke et al., 2012). These additional TMS 
parameters have been found to correlate with clinical disability (EDSS), and therefore, 
are being considered as potential biomarkers to monitor disability (Sahota, Prabhakar et 
al., 2005; Vucic, Burke et al., 2012; Nantes, Zhong et al., 2016). 
 
3.4.1 Central Motor Conduction Time 
Central motor conduction time is the length of time it takes for the TMS signal to be 
transmitted through the motor pathway to the muscle of interest (Rossini, Barker et al., 
1994). Studies have reported significantly longer central motor conduction time among 
people with MS compared to healthy controls (Tataroglu, Genc et al., 2003; Conte, Lenzi 
et al., 2009). Additionally, Sahota and colleagues (2005) showed that, in 30 patients with 
MS with acute relapse or progressive disease, central motor conduction time improved in 
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patients who displayed both pyramidal and cerebellar clinical improvements (Sahota, 
Prabhakar et al., 2005). While our research only involved investigations of CSP, RMT 
and AMT, there is research which  supports central motor conduction time as a potential 
biomarker of disability. Whether this measure would be able to track disease progression 
among those who experience non-motor symptoms (cognitive or sensory) is worthy of 
further investigation.  
 
3.4.2 Measures of Intracortical Inhibition  
Short and long-interval intracortical inhibition parameters are other noteworthy 
TMS measures that are collected using a TMS technique called paired-pulse at different 
interstimulus intervals (Zipser et al., 2018). This technique involves priming the brain 
with a subthreshold TMS pulse that can either suppress or potentiate the subsequent 
stimulus depending on the interstimulus interval chosen. It is known that short 
intracortical inhibition takes place at 20ms intervals and long intracortical inhibition at 
200ms intervals (Ni & Chen, 2015). In particular, short-interval inhibition has been found 
to represent a period of motor cortex inhibition mediated by intracortical  
interneural circuits of inhibition by GABA receptors  and has been reported as reduced or 
non-existent in neurological disorders such as Alzheimer’s (Di Lazzaro, Oliviero et al., 
2004) and MS (Vucic, Burke et al., 2012). These measures may be relevant to MS 
research because CNS degeneration is partially attributed to excitotoxicity, caused by 
overactivity of the CNS neurotransmitter glutamate and insufficient inhibitory inputs to 
counterbalance inhibitory signals from GABA, an inhibitory neurotransmitter (Lazo-
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Gomez, Velázquez et al., 2019). Both short and long-interval intracortical inhibition 
parameters provide insight into this inhibitory transmission within the CNS, however, we 
will direct our attention to short-interval intracortical inhibition; a measure that is 
showing a growing body of evidence demonstrating its efficacy as a biomarker of 
disability in MS.  
 
3.4.2.1 Short-Interval Intracortical Inhibition  
In MS research, short-interval intracortical inhibition has been identified as an 
important measure that correlates with disability (Vucic, Burke et al., 2012; Nantes, 
Zhong et al., 2016). Recent research demonstrated that short-interval intracortical 
inhibition was significantly decreased in patients with secondary progressive MS (n=15) 
as compared to those with relapsing-remitting MS (n=25) and healthy controls (n=66). 
Also, decreased short-interval intracortical inhibition correlated with greater disability 
(measured by the EDSS) for those with secondary progressive MS (Vucic, Burke et al., 
2012). In another study, Nantes and colleagues (2016) assessed short-interval 
intracortical inhibition in 36 patients with MS and detected abnormally low short-interval 
intracortical inhibition in people with relapsing-remitting MS  (n=22) and progressive 
MS (n=14) as compared to healthy controls (n=18) (Nantes, Zhong et al., 2016). Nantes 
and colleagues (2016) proposed that short-interval intracortical inhibition detects cortical 
damage, as seen in those with secondary progressive MS and may also be sensitive to 
white matter tract damage as seen in relapsing-remitting MS. Accordingly, these studies 
illustrate that short-interval intracortical inhibition detects degeneration within the brain, 
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linked to clinical disability. It is important to remember that the measure used in these 
studies, EDSS, is a subjective categorical rating scale that is notoriously insensitive to 
subtle symptom worsening (Hohol, Orav et al., 1995). Whether intracortical inhibition 
could predict measures of symptom severity such as walking speed, cognitive changes or 
sensory symptoms is not known. In addition to the classically measured CSP and AMT, 
future studies should include other TMS parameters such as central motor conduction 
time and short-interval intracortical inhibition to ensure potentially meaningful variables 
for monitoring MS disability. 
 
3.5 FUTURE DIRECTIONS AND IMPLICATIONS 
 3.5.1 TMS: A Future Component of the ‘No Evidence of Disease 
Activity’ Paradigm? 
The term ‘No Evidence of Disease Activity’ or NEDA has been recently coined in 
order to set a new standard for MS disease-modifying therapies (Giovannoni, Turner et 
al., 2015). In order to confirm that a treatment provides complete protection against 
disease progression, three NEDA criteria have to be met: (1) there are no relapses, (2) 
there is no disability progression and (3) there is no MRI activity indicating inflammation 
and lesions (Havrdova, Galetta et al., 2009, Giovannoni, Cook et al., 2011).  Recent 
consensus supports adding a fourth criteria; no evidence of brain atrophy (Guevara, 
Garrido et al., 2019). Researchers noted that although this paradigm provides optimal 
treatment monitoring outcomes, NEDA will continue to be modified in order to evolve 
with advancements in technology (Giovannoni, Turner et al., 2015). High resolution MRI 
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provides definitive evidence of whether a patient is experiencing new lesions or atrophy 
(structural change), but it is limited by its inability to identify changes in brain function. 
The “functional” measure is currently relying on the clinical exam (EDSS change); 
however, our findings illustrate that TMS measures CSP and AMT can predict disease 
severity measures of MS (walking speed, perceived physical impact of MS and cognitive 
impairment) for those with cognitive and motor symptoms, with more precision than the 
standard EDSS. TMS provides a window on how lesions and atrophy are affecting brain 
network integrity; important information that can be used as metrics in order to test the 
effectiveness of medication and treatment therapies in MS. Having said this, our results 
support that the TMS measures that we investigated did not have the capability to predict 
disease severity for sensory and asymptomatic profiles of MS. Future research should 
build upon existing and emerging TMS measures which could be incorporated into 
NEDA criteria. Overall, as a non-invasive method to measure corticospinal tract integrity 
and brain function, TMS has the potential to contribute missing functional information 
and strengthen the NEDA criteria.  
 
3.5.2 The Use of TMS in a Clinical Setting 
3.5.2.1 TMS Addressing Personalized Medicine  
The foundation of personalized medicine in MS is to fully understand one’s current 
level of disability. Evidence suggests that treatments geared towards specific impairments 
work better than generalized programs (Rannisto, Rosti-Otajärvi et al., 2015). 
Nevertheless, personal medicine in MS is made challenging due to the vast heterogeneity 
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and unpredictability of the disease because of various combinations of lesion location and 
burden within the CNS (Gafson, Craner et al., 2017). In addition, different levels of brain 
reserve and the ability for compensation between people make lesions of the same area 
display different effects on function between individuals. As previously discussed, 
limitations of EDSS have been brought to light concerning sensitivity, heterogeneity, and 
inter-rater reliability. Thus, a new biomarker for disability in MS is crucial in order to 
establish the foundation for personalized medicine; where the frontier of research lies.  
It is important to note that while we display preliminary evidence of the benefits 
of TMS sensitivity to symptom severity measures as compared to EDSS, clinical 
translation from EDSS to TMS comes with many challenges. EDSS has many benefits, 
being that it is easy to administer, cheap and very time efficient. On the other hand, TMS 
requires expensive equipment, a TMS technician, and interpretation. Future research 
would be necessary to validate the clinical value of TMS as a biomarker of disability over 
time, as compared to the EDSS. While these challenges are evident, the emphasis of 
personalized medicine in the field of MS is a necessity. If TMS is proven to be a sensitive 
biomarker of disability, allowing assessment of the effectiveness of new medication and 
rehabilitation treatment strategies, then the weight of personalized medicine achieved 
from TMS may outweigh the challenges that come with it.  
 
3.6 LIMITATIONS 
There are some limitations to this study that could influence the present results. 
Although our study is novel in terms of separating people with MS into main categories of 
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MS symptoms from the neurologist reports, these classifications were not always concrete. 
An evaluation of each participant’s neurological report was completed; however, it can be 
challenging to determine a singular defining clinical profile due to the heterogeneity of 
MS. Thus, classifying people with MS by their main clinical deficit had a level of 
subjectivity. Another limitation was that participants drug-modifying therapy was not 
collected or analyzed in this research. Some drug modifying therapies impact glutamate 
levels in the brain such as Fingolimod, which can protect neurons from glutamatergic 
excitotoxic damage (Landi et al., 2015). In this case, these drug-modifying therapies may 
have an effect on TMS measures and should be taken into consideration in future TMS 
research. In our study, the participant’s weaker side was determined based on the hand with 
the lowest combined grip and pinch strength measures (grip + pinch). It would be 
preferable for prospective research to incorporate participants MRI scan in order to detect 
patients weaker/stronger side providing more accuracy to the side with more inflammation 
and degeneration.  
 There were some notable limitations involving our interpretation of TMS 
parameters. We aimed to compare our TMS measures to other studies, yet, there are several 
different protocols for the collection of these measures that limited this comparison. For 
example, our participants used 10% maximum contraction during AMT collection while 
other studies have used 50% maximum contraction (Haug & Kukowski, 1994; Tataroglu, 
Genc et al., 2003). Moreover, even differences in the type of coil used can produce different 
TMS results due to different cortical elements being activated (Taylor, Allen et al., 1997). 
For instance, it has been shown that the CSP is shorter with the figure-of-eight coil as 
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opposed to the round coil due to different cortical elements being activated, making it 
difficult to compare our results to clinical studies using a round coil (Oozumi, Ito et al., 
1992).  Additionally, the  lack of healthy controls in this study limited our interpretation of 
the results. In other words, although we know that the motor group displayed prolonged 
CSP as compared to other clinical MS profiles, we are unsure if the CSP would have been 
longer or shorter than CSP of healthy controls.  
Lastly, it is important to acknowledge the sample size of this clinical population. 
When performing linear and stepwise regressions, there was a range from 7 participants to 
5 predictors (tables 2.2/2.3: asymptomatic group), to 20 participants and 4 predictors 
(motor-cognitive group in step-wise analysis). Thus, these regressions results do pose a 
serious risk of type 1 errors. Nonetheless, the data reported in this study could be a useful 
foundation for creating a larger scale study. To summarize, given the various TMS 
procedures, the implication of a standardized TMS protocol for MS research should be 
warranted to increase reproducibility. Additionally, studies should incorporate healthy 
controls for optimal comparison between studies to allow for greater opportunity to 
elucidate the capability of TMS as a biomarker of disability in MS.  
 
3.7 CONCLUSION 
To our knowledge, we are the first research group to take into consideration the 
heterogeneity of MS by separating participants into the four main categories of motor, 
cognitive, sensory and asymptomatic profiles when using TMS. First, we investigated the 
ability of TMS to distinguish people with MS by main clinical profiles of MS including 
 81 
motor, cognitive, sensory and asymptomatic profiles. Secondly, we determined if TMS 
measures predicted clinical measures of disease severity, beyond the EDSS. We found 
that two TMS measures CSP and AMT were useful for people with MS with motor and 
cognitive symptoms. Additionally, in the motor and cognitive group, CSP was the best 
predictor of walking speed, while AMT was the best predictor cognitive impairment and 
perceived physical impact of MS. Further, we suggest that that TMS may be predictive 
for symptom severity measures in those with cognitive symptoms of MS due to possible 
detection of subtle abnormalities within the CST. 
Findings from this study covered the first steps necessary to evaluate the 
competence of TMS as a sensitive biomarker of disability in comparison to the EDSS, 
which has its recognized weaknesses. The next necessary step involves the development 
of a protocol to test the validity and reliability of TMS within these clinical profiles of 
MS. With further investigation that addresses our limitations, TMS may be found to be a 
valuable biomarker that can be used to track sensitive changes in disease progression and 
improvement in MS for people with motor and cognitive symptoms.  
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